144701-48-4 | Telmisartan

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$6.00	$4.00
1g	98%	in stock	$8.00	$5.00
5g	98%	in stock	$25.00	$17.00
25g	98%	in stock	$36.00	$26.00
500g	98%	in stock	$572.00	$400.00

Description

• Catalog Number: AA72441
• Chemical Name: Telmisartan
• CAS Number: 144701-48-4
• Molecular Formula: C33H30N4O2
• Molecular Weight: 514.6169
• MDL Number: MFCD00918125
• SMILES: CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2
• NSC Number: 759811

Computed Properties

• Complexity: 831
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 39
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• XLogP3: 6.9

Literature

• Differential regulation of tefluthrin and telmisartan on the gating charges of I(Na) activation and inactivation as well as on resurgent and persistent I(Na) in a pituitary cell line (GH(3)).

  Toxicology letters 20180315

• Telmisartan ameliorates carbon tetrachloride-induced acute hepatotoxicity in rats.

  Environmental toxicology 20170201

• TLR4/MyD88/NF-κB signaling and PPAR-γ within the paraventricular nucleus are involved in the effects of telmisartan in hypertension.

  Toxicology and applied pharmacology 20160815

• Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays.

  Toxicology in vitro : an international journal published in association with BIBRA 20151225

• Transmembrane transport of steviol glucuronide and its potential interaction with selected drugs and natural compounds.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20151201

• Protective effect of telmisartan treatment against arsenic-induced testicular toxicity in rats.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20150701

• Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease.

  PloS one 20140101

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.

  Neuropharmacology 20131001

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer's disease type: possible involvement of PPAR-γ agonistic property.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20130601

• Captopril and telmisartan treatments attenuate cadmium-induced testicular toxicity in rats.

  Fundamental & clinical pharmacology 20130401

• Effect of angiotensin II type 1 receptor blocker on renal function, arterial blood pressure and parathyroid hormone related protein over expression in cadmium induced nephrotoxicity in adult male rats.

  International journal of physiology, pathophysiology and pharmacology 20130101

• Identification of old drugs as potential inhibitors of HIV-1 integrase - human LEDGF/p75 interaction via molecular docking.

  Journal of molecular modeling 20121201

• Effect of angiotensin II receptor antagonist telmisartan on detrusor overactivity in rats with bladder outlet obstruction.

  Urology 20121101

• Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques.

  Nuclear medicine and biology 20121101

• Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20121101

• Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination in the treatment of hypertension.

  Expert opinion on pharmacotherapy 20121101

• Telmisartan treatment attenuates arsenic-induced hepatotoxicity in mice.

  Toxicology 20121028

• Therapeutic role of telmisartan against acetaminophen hepatotoxicity in mice.

  European journal of pharmacology 20121015

• Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue: A possible link to anti-metabolic effects.

  European journal of pharmacology 20121005

• Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.

  The Prostate 20121001

• The intrinsic PEDF is regulated by PPARγ in permanent focal cerebral ischemia of rat.

  Neurochemical research 20121001

• The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.

  Pharmacological research 20121001

• Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats.

  Journal of hypertension 20121001

• Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT₁ receptor in the rostral ventrolateral medulla of hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120901

• Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography.

  Pharmaceutical research 20120901

• Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20120901

• Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy.

  Stroke 20120901

• Relationship between telmisartan dose and glycaemic control in Japanese patients with type 2 diabetes mellitus and hypertension: a retrospective study.

  Clinical drug investigation 20120901

• Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).

  Circulation 20120821

• Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.

  Acta diabetologica 20120801

• Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20120801

• Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3.

  Nuclear medicine and biology 20120801

• Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.

  Journal of cardiovascular pharmacology 20120801

• Telmisartan improves kidney function through inhibition of the oxidative phosphorylation pathway in diabetic rats.

  Journal of molecular endocrinology 20120801

• Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120801

• A novel method for the determination of the site of glucuronidation by ion mobility spectrometry-mass spectrometry.

  Drug metabolism and disposition: the biological fate of chemicals 20120801

• Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.

  Journal of hypertension 20120801

• Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: a retrospective cohort study using a Korean clinical research database.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20120801

• Effect of peroxisome proliferator activated receptor γ agonist on angiotensin converting enzyme 2 mRNA expression in monocyte-derived macrophages of essential hypertensive patients.

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20120801

• Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.

  Expert review of cardiovascular therapy 20120801

• Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.

  Bioorganic & medicinal chemistry 20120715

• Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.

  British journal of clinical pharmacology 20120701

• Structural basis for telmisartan-mediated partial activation of PPAR gamma.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120701

• Experimental hypertension induced vascular dementia: pharmacological, biochemical and behavioral recuperation by angiotensin receptor blocker and acetylcholinesterase inhibitor.

  Pharmacology, biochemistry, and behavior 20120701

• Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial.

  Clinical therapeutics 20120701

• Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers.

  Clinical therapeutics 20120701

• Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.

  Advances in therapy 20120701

• An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome.

  International journal of cardiology 20120628

• Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.

  European journal of pharmacology 20120615

• Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials.

  International journal of cardiology 20120614

• Differences in angiotensin convertase enzyme (ACE) activity and expression may contribute to shorter event free period after coronary artery bypass graft surgery.

  Cardiovascular therapeutics 20120601

• Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.

  Journal of clinical pharmacy and therapeutics 20120601

• Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium.

  Cellular signalling 20120601

• Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.

  Journal of cardiovascular pharmacology 20120601

• Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size.

  Clinical cardiology 20120601

• Different effects of telmisartan and valsartan on human aortic vascular smooth muscle cell proliferation.

  Chinese medical journal 20120601

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120501

• Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.

  American journal of hypertension 20120501

• Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation.

  Basic research in cardiology 20120501

• Telmisartan in the management of diabetic nephropathy: a contemporary view.

  Current diabetes reviews 20120501

• Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: the ASSERTIVE double-blind, randomized study.

  Journal of hypertension 20120501

• Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.

  Hypertension (Dallas, Tex. : 1979) 20120501

• Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension.

  Journal of hypertension 20120501

• Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.

  Journal of hypertension 20120501

• Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.

  European review for medical and pharmacological sciences 20120501

• Atrial expression of the CCN1 and CCN2 proteins in chronic heart failure.

  Folia histochemica et cytobiologica 20120424

• Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials.

  International journal of cardiology 20120419

• Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials.

  International journal of cardiology 20120405

• Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20120403

• Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease.

  Geriatrics & gerontology international 20120401

• Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.

  British journal of pharmacology 20120401

• Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome.

  Diabetes, obesity & metabolism 20120401

• Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study.

  Clinical and experimental nephrology 20120401

• Modulation of urinary peptidome in humans exposed to high altitude hypoxia.

  Molecular bioSystems 20120401

• Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model.

  The Journal of pharmacology and experimental therapeutics 20120401

• Left bundle branch block, an old-new entity.

  Journal of cardiovascular translational research 20120401

• Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

  Drug metabolism and disposition: the biological fate of chemicals 20120401

• Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?

  Journal of hypertension 20120401

• Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20120401

• Is there room for dual blockade of the renin-angiotensin-aldosterone system?

  Journal of hypertension 20120401

• Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.

  European journal of heart failure 20120401

• Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study.

  Journal of clinical hypertension (Greenwich, Conn.) 20120401

• Telmisartan-induced eNOS gene expression is partially independent of its PPAR-gamma agonist property.

  Clinical and investigative medicine. Medecine clinique et experimentale 20120401

• Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures.

  Advances in therapy 20120401

• Hemodynamic evaluation and anti-hypertensive schemes used in puerperal women following pre-eclampsia.

  Mymensingh medical journal : MMJ 20120401

• Analysis of cytotoxicity induced by proinflammatory cytokines in the human alveolar epithelial cell line A549.

  Bioscience trends 20120401

• Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy.

  Acta cardiologica 20120401

• Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.

  European review for medical and pharmacological sciences 20120401

• Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials.

  International journal of cardiology 20120322

• Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs.

  Molecular pharmaceutics 20120305

• Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.

  Journal of cardiovascular pharmacology and therapeutics 20120301

• New roles for renin and prorenin in heart failure and cardiorenal crosstalk.

  Heart failure reviews 20120301

• Abilities of candesartan and other AT(1) receptor blockers to impair angiotensin II-induced AT(1) receptor activation after wash-out.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301

• Angiotensin II type-1 receptor-JAK/STAT pathway mediates the induction of visfatin in angiotensin II-induced cardiomyocyte hypertrophy.

  The American journal of the medical sciences 20120301

• Telmisartan decreases atrial electromechanical delay in patients with newly diagnosed essential hypertension.

  Journal of electrocardiology 20120301

• HIV-associated nephropathy: role of AT2R.

  Cellular signalling 20120301

• Telmisartan as metabolic modulator: a new perspective in sports doping?

  Journal of strength and conditioning research 20120301

• Synergistic effects of telmisartan and pyridoxamine on early renal damage in spontaneously hypertensive rats.

  Molecular medicine reports 20120301

• Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out mice.

  Journal of molecular and cellular cardiology 20120301

• Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation.

  Endocrinology 20120301

• The TALENT Study.

  Expert opinion on pharmacotherapy 20120301

• Telmisartan-induced lithium intoxication in a patient with schizoaffective disorder.

  Psychiatry and clinical neurosciences 20120301

• Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.

  Clinical therapeutics 20120301

• [Contemporary presentation of unusual adverse events during telmisartan therapy].

  Recenti progressi in medicina 20120301

• The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications.

  Postgraduate medicine 20120301

• Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma.

  Acta pharmaceutica (Zagreb, Croatia) 20120301

• A case of swallow syncope associated with cold beverage ingestion.

  Korean circulation journal 20120301

• Enhancement of dissolution of Telmisartan through use of solid dispersion technique - surface solid dispersion.

  Journal of pharmacy & bioallied sciences 20120301

• Hypertension without renovascular stenosis: a rare case of abdominal aorta coarctation treated with percutaneous transluminal angioplasty.

  Archives of medical science : AMS 20120227

• Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis.

  Life sciences 20120213

• Four novel UCP3 gene variants associated with childhood obesity: effect on fatty acid oxidation and on prevention of triglyceride storage.

  International journal of obesity (2005) 20120201

• Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats.

  Metabolism: clinical and experimental 20120201

• Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.

  European journal of clinical pharmacology 20120201

• Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1.

  Cellular signalling 20120201

• Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120201

• Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance.

  Hypertension (Dallas, Tex. : 1979) 20120201

• Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.

  Hypertension (Dallas, Tex. : 1979) 20120201

• Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.

  Stroke 20120201

• Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients.

  JACC. Cardiovascular interventions 20120201

• A pharmacologically-based array to identify targets of cyclosporine A-induced toxicity in cultured renal proximal tubule cells.

  Toxicology and applied pharmacology 20120115

• Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

  Journal of the American College of Cardiology 20120103

• The therapeutic potential of G-CSF in pressure overload induced ventricular reconstruction and heart failure in mice.

  Molecular biology reports 20120101

• Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension.

  The American journal of the medical sciences 20120101

• Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120101

• Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data.

  Drug metabolism and pharmacokinetics 20120101

• Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?

  QJM : monthly journal of the Association of Physicians 20120101

• Autophagy as a therapeutic target in diabetic nephropathy.

  Experimental diabetes research 20120101

• Cultural Considerations: Pharmacological and Nonpharmacological Means for Improving Blood Pressure Control among Hispanic Patients.

  International journal of hypertension 20120101

• The Association between Hypertension and Dementia in the Elderly.

  International journal of hypertension 20120101

• Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes.

  Journal of hypertension 20120101

• Surgical management of uterine fibroids at aminu kano teaching hospital.

  Obstetrics and gynecology international 20120101

• Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

• A Novel Cellular Model to Study Angiotensin II AT2 Receptor Function in Breast Cancer Cells.

  International journal of peptides 20120101

• Optimization of comorbidity therapy to achieve sustained viral response in HCV patients.

  Hepato-gastroenterology 20120101

• Neuroprotective effects of lutein in the retina.

  Current pharmaceutical design 20120101

• Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.

  Cardiovascular diabetology 20120101

• The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.

  BMJ (Clinical research ed.) 20120101

• Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.

  BMJ (Clinical research ed.) 20120101

• Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

• Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials.

  Patient preference and adherence 20120101

• Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review.

  Indian journal of endocrinology and metabolism 20120101

• [Observation on curative effect of glomerular pathological proteinuria treated with heat-producing needling].

  Zhongguo zhen jiu = Chinese acupuncture & moxibustion 20120101

• Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis.

  International journal of molecular sciences 20120101

• PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways.

  PPAR research 20120101

• Small vessel cerebrovascular disease: the past, present, and future.

  Stroke research and treatment 20120101

• An angiotensin II type 1 receptor blocker prevents renal injury via inhibition of the Notch pathway in Ins2 Akita diabetic mice.

  Experimental diabetes research 20120101

• Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.

  Journal of neuroinflammation 20120101

• Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension.

  Kidney & blood pressure research 20120101

• Differential pharmacology and benefit/risk of azilsartan compared to other sartans.

  Vascular health and risk management 20120101

• Therapeutic options for the treatment of hypertension in children and adolescents.

  Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 20120101

• Angiotensin receptor blockers in clinical practice--implications of the ONTARGET study.

  The Journal of international medical research 20120101

• New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.

  Integrated blood pressure control 20120101

• Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.

  Mediators of inflammation 20120101

• Experimental models of type-2 diabetic nephropathy.

  Experimental diabetes research 20120101

• ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling.

  Nephron extra 20120101

• The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.

  International journal of vascular medicine 20120101

• What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

  Cardiovascular diabetology 20120101

• Renin angiotensin system: A novel target for migraine prophylaxis.

  Indian journal of pharmacology 20120101

• Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.

  BMJ (Clinical research ed.) 20120101

• Emerging drug combinations to optimize renovascular protection and blood pressure goals.

  International journal of nephrology and renovascular disease 20120101

• Angiotensin II facilitates breast cancer cell migration and metastasis.

  PloS one 20120101

• Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction.

  International journal of inflammation 20120101

• [Critically appraised article].

  Revista medica de Chile 20120101

• Cardiovascular magnetic resonance in systemic hypertension.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20120101

• [Telmisartan effect's on remodelling bone markers in hypertensive patients].

  Nutricion hospitalaria 20120101

• Moxifloxacin (avelox) induced thrombotic thrombocytopenic purpura.

  Case reports in medicine 20120101

• Simultaneous Analysis of Losartan Potassium, Amlodipine Besylate, and Hydrochlorothiazide in Bulk and in Tablets by High-Performance Thin Layer Chromatography with UV-Absorption Densitometry.

  Journal of analytical methods in chemistry 20120101

• [New effects of telmisartan, an angiotensin 2 receptor blocker, in the treatment of arterial hypertension with metabolic disorders].

  Klinicheskaia meditsina 20120101

• PEDF in diabetic retinopathy: a protective effect of oxidative stress.

  Journal of biomedicine & biotechnology 20120101

• Astragalus injection for hypertensive renal damage: a systematic review.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20120101

• Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study.

  BMJ open 20120101

• Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways.

  Journal of neuroinflammation 20120101

• Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy.

  Experimental diabetes research 20120101

• Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment.

  International journal of hypertension 20120101

• Critical evaluation of the efficacy and tolerability of azilsartan.

  Vascular health and risk management 20120101

• Age-related changes in the retinal pigment epithelium (RPE).

  PloS one 20120101

• Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.

  International journal of hepatology 20120101

• Choroidal detachment after uncomplicated small incision cataract surgery.

  Case reports in ophthalmology 20120101

• Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension.

  International journal of hypertension 20120101

• [Dynamic analysis of pharmacokinetics of orally administered drugs using positron emission tomography].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20120101

• Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response.

  BMC cardiovascular disorders 20120101

• Effect of telmisartan on the expression of adiponectin receptors and nicotinamide adenine dinucleotide phosphate oxidase in the heart and aorta in type 2 diabetic rats.

  Cardiovascular diabetology 20120101

• Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.

  PloS one 20120101

• Telmisartan counteracts TGF-β1 induced epithelial-to-mesenchymal transition via PPAR-γ in human proximal tubule epithelial cells.

  International journal of clinical and experimental pathology 20120101

• Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.

  PloS one 20120101

• Renal outcome in equipotent antihypertensive treatment with telmisartan, ramipril and in combination in SHR-SP rats.

  Clinical laboratory 20120101

• Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension.

  International journal of general medicine 20120101

• [High blood pressure in the morning].

  MMW Fortschritte der Medizin 20111208

• Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension.

  Drugs 20111203

• Effect of cryogrinding on chemical stability of the sparingly water-soluble drug furosemide.

  Pharmaceutical research 20111201

• Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy.

  Hypertension research : official journal of the Japanese Society of Hypertension 20111201

• The loss of muscle mass and sarcopenia: non hormonal intervention.

  Experimental gerontology 20111201

• Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

  Diabetologia 20111201

• Telmisartan: just an antihypertensive agent? A literature review.

  Expert opinion on pharmacotherapy 20111201

• Nifedipine and telmisartan for the treatment of hypertension: the TALENT study.

  Expert review of cardiovascular therapy 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Prediction of drug combinations by integrating molecular and pharmacological data.

  PLoS computational biology 20111201

• Robot-assisted posterior retroperitoneoscopic adrenalectomy: single port access.

  Journal of the Korean Surgical Society 20111201

• Impact and Therapeutic Potential of PPARs in Alzheimer's Disease.

  Current neuropharmacology 20111201

• Level of systolic blood pressure within the normal range and risk of recurrent stroke.

  JAMA 20111116

• Risk of cancer associated with the use of angiotensin II-receptor blockers.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111115

• Development of a validated liquid chromatographic method for determination of related substances of telmisartan in bulk drugs and formulations.

  Journal of pharmaceutical and biomedical analysis 20111101

• Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients.

  Hypertension research : official journal of the Japanese Society of Hypertension 20111101

• Relationship between QRS duration and left ventricular mass and volume in patients at high cardiovascular risk.

  Heart (British Cardiac Society) 20111101

• Progesterone and 1,25-dihydroxyvitamin D₃ inhibit endometrial cancer cell growth by upregulating semaphorin 3B and semaphorin 3F.

  Molecular cancer research : MCR 20111101

• Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.

  European heart journal 20111101

• Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study.

  Current medical research and opinion 20111101

• Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients.

  Expert opinion on pharmacotherapy 20111101

• Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure.

  Acta pharmacologica Sinica 20111101

• Review: a single-pill combination of telmisartan plus amlodipine for the treatment of hypertension.

  Postgraduate medicine 20111101

• A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.

  The Indian journal of medical research 20111101

• Pilot data on telmisartan short-term effects on glucose metabolism in the olfactory tract in Alzheimer's disease.

  Brain and behavior 20111101

• Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).

  Circulation 20111018

• Is a blood pressure target of <130/80 mm Hg still appropriate for high-risk patients?

  Circulation 20111018

• The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan.

  Molecular pharmaceutics 20111003

• 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension.

  Journal of human hypertension 20111001

• Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111001

• Endoplasmic reticulum stress caused by left ventricular hypertrophy in rats: effects of telmisartan.

  The American journal of the medical sciences 20111001

• The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance.

  Diabetes research and clinical practice 20111001

• Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan.

  Arteriosclerosis, thrombosis, and vascular biology 20111001

• The impact of hepatic uptake on the pharmacokinetics of organic anions.

  Drug metabolism and disposition: the biological fate of chemicals 20111001

• High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.

  Hypertension (Dallas, Tex. : 1979) 20111001

• Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients.

  Current medical research and opinion 20111001

• Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity.

  Saudi medical journal 20111001

• Telmisartan versus valsartan in patients with hypertension: effects on cardiovascular, metabolic, and inflammatory parameters.

  Korean circulation journal 20111001

• Angiopoietin-1 gene therapy attenuates hypertension and target organ damage in nitric oxide synthase inhibited spontaneously hypertensive rats.

  Korean circulation journal 20111001

• Management of diabetic hypertensives.

  Indian journal of endocrinology and metabolism 20111001

• Exploring the potential of telmisartan in chronic constriction injury-induced neuropathic pain in rats.

  European journal of pharmacology 20110930

• Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20110901

• Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability.

  Journal of cardiology 20110901

• Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.

  Heart (British Cardiac Society) 20110901

• Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study.

  Diabetes care 20110901

• Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration.

  Hypertension (Dallas, Tex. : 1979) 20110901

• The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.

  Pharmacogenetics and genomics 20110901

• Coexistence of functional angiotensin II type 2 receptors mediating both vasoconstriction and vasodilation in humans.

  Journal of hypertension 20110901

• Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD.

  PLoS genetics 20110901

• Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110801

• Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose.

  Pharmacogenetics and genomics 20110801

• Telmisartan for the management of patients at high cardiovascular risk.

  Current medical research and opinion 20110801

• Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin.

  American journal of nephrology 20110801

• Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).

  Advances in therapy 20110801

• Target blood pressure in diabetes patients with hypertension--what is the accumulated evidence in 2011?

  Journal of Zhejiang University. Science. B 20110801

• Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones.

  Diabetes & metabolism journal 20110801

• Letter: the effect of an Angiotensin receptor blocker on arterial stiffness in type 2 diabetes mellitus patients with hypertension (diabetes metab j 2011;35:236-42).

  Diabetes & metabolism journal 20110801

• [Effects of telmisartan on nonalcoholic steatohepatitis rat model by activating peroxisome proliferator-activated receptor r].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20110801

• Investigation of physicochemical factors affecting the stability of a pH-modulated solid dispersion and a tablet during storage.

  International journal of pharmaceutics 20110729

• Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.

  Journal of medicinal chemistry 20110714

• Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.

  Biochemical and biophysical research communications 20110708

• Primary stroke prevention and hypertension treatment: which is the first-line strategy?

  Neurology international 20110705

• Protective effect of telmisartan against cadmium-induced nephrotoxicity in mice.

  Life sciences 20110704

• Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway.

  Journal of cellular and molecular medicine 20110701

• Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.

  American journal of hypertension 20110701

• Species independence in brain tissue binding using brain homogenates.

  Drug metabolism and disposition: the biological fate of chemicals 20110701

• In vitro interaction study of retinoic acid isomers with telmisartan and amlodipine by equilibrium dialysis method using UV spectroscopy.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20110701

• Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice.

  Pancreas 20110701

• Emerging benefits of AT1 receptor antagonists with pleiotropic anti-inflammatory activity.

  American journal of hypertension 20110701

• Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study.

  Journal of clinical hypertension (Greenwich, Conn.) 20110701

• The significance of the j-curve in hypertension and coronary artery diseases.

  Korean circulation journal 20110701

• [Effects of telmisartan and pyridoxamine on abdominal aorta vascular remodeling in spontaneously hypertensive rats].

  Zhonghua xin xue guan bing za zhi 20110701

• Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.

  European journal of pharmacology 20110625

• Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice.

  Biochemical and biophysical research communications 20110624

• Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.

  Journal of medicinal chemistry 20110623

• First automatic radiosynthesis of 11C labeled Telmisartan using a multipurpose synthesizer for clinical research use.

  Annals of nuclear medicine 20110601

• Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.

  Diabetes, obesity & metabolism 20110601

• Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.

  British journal of pharmacology 20110601

• Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.

  Metabolic syndrome and related disorders 20110601

• Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma.

  Laboratory investigation; a journal of technical methods and pathology 20110601

• Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.

  Arteriosclerosis, thrombosis, and vascular biology 20110601

• Autonomic imbalance: prophet of doom or scope for hope?

  Diabetic medicine : a journal of the British Diabetic Association 20110601

• Identification and management of albuminuria in the primary care setting.

  Journal of clinical hypertension (Greenwich, Conn.) 20110601

• Telmisartan protects against insulin resistance by attenuating inflammatory response in rats.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20110601

• Telmisartan in high-risk cardiovascular patients. No need to change standard practice.

  Prescrire international 20110601

• New clinical concepts after the ONTARGET trial.

  Expert review of cardiovascular therapy 20110601

• Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.

  Chinese medical journal 20110601

• Proteinuria in an African HIV-infected patient: effects of telmisartan.

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20110601

• Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.

  Journal of managed care pharmacy : JMCP 20110601

• Metabolic improvement by telmisartan beyond angiotensin receptor blockade: role of adipokines.

  Arquivos brasileiros de endocrinologia e metabologia 20110601

• Hyponatremia associated with bupropion.

  Electrolyte & blood pressure : E & BP 20110601

• Differential levels of circulating progenitor cells in acute coronary syndrome patients with a first event versus patients with recurring events.

  International journal of cardiology 20110519

• ACP journal club. In hemodialysis patients with CHF, adding telmisartan to standard ACE inhibitors reduced CHD mortality and admissions.

  Annals of internal medicine 20110517

• Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.

  Drug metabolism and disposition: the biological fate of chemicals 20110501

• Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS).

  Diabetologia 20110501

• Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway.

  American journal of physiology. Cell physiology 20110501

• CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.

  Drug metabolism and disposition: the biological fate of chemicals 20110501

• Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action.

  Free radical research 20110501

• Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice.

  Endocrinology 20110501

• Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.

  Canadian journal of physiology and pharmacology 20110501

• Roles of MgO release from polyethylene glycol 6000-based solid dispersions on microenvironmental pH, enhanced dissolution and reduced gastrointestinal damage of telmisartan.

  Archives of pharmacal research 20110501

• Telmisartan: a review of its use in cardiovascular disease prevention.

  Drugs 20110416

• The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.

  Journal of human hypertension 20110401

• Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications.

  American journal of hypertension 20110401

• Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.

  Cardiovascular research 20110401

• Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation.

  Cell and tissue research 20110401

• Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.

  Diabetes care 20110401

• Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.

  Journal of hypertension 20110401

• Telmisartan attenuates isoproterenol-induced cardiac remodeling in rats via regulation of cardiac adiponectin expression.

  Acta pharmacologica Sinica 20110401

• Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.

  Clinical cardiology 20110401

• Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.

  Circulation 20110315

• Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110301

• Endothelium-dependent vasomotor effects of telmisartan in isolated rat femoral arteries.

  Pharmacological research 20110301

• Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in zucker Fatty rats by suppressing advanced glycation end product receptor axis.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20110301

• In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.

  The Journal of pharmacology and experimental therapeutics 20110301

• Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ.

  Current vascular pharmacology 20110301

• Pleiotropic effects of ARB on dyslipidemia.

  Current vascular pharmacology 20110301

• Telmisartan improves insulin resistance in patients with low cytokine levels.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20110301

• Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study.

  Journal of hypertension 20110301

• Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats.

  Journal of cardiovascular pharmacology 20110301

• Dietary salt intake and mortality in patients with type 2 diabetes.

  Diabetes care 20110301

• Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study.

  Annals of internal medicine 20110301

• Modulation of metabolic and cardiac dysfunctions by insulin sensitizers and angiotensin receptor blocker in rat model of type 2 diabetes mellitus.

  Canadian journal of physiology and pharmacology 20110301

• Comparative study of telmisartan tablets prepared via the wet granulation method and pritor™ prepared using the spray-drying method.

  Archives of pharmacal research 20110301

• Telmisartan for the reduction of cardiovascular morbidity and mortality.

  Expert review of clinical pharmacology 20110301

• Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress.

  European journal of pharmacology 20110210

• Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan.

  Journal of clinical pharmacy and therapeutics 20110201

• Development and validation of an improved method for the quantitation of sertraline in human plasma using LC-MS-MS and its application to bioequivalence studies.

  Journal of chromatographic science 20110201

• Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression.

  Regulatory peptides 20110117

• Simultaneous determination of ramipril, ramiprilat and telmisartan in human plasma using liquid chromatography tandem mass spectrometry.

  Talanta 20110115

• Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions.

  Toxicology 20110111

• Osteogenic differentiation of mesenchymal stem cells is preserved by partial, but not full peroxisome proliferator-activated receptor-γ agonist.

  International journal of cardiology 20110107

• Unique 'delta lock' structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor.

  Biochemical and biophysical research communications 20110107

• The Ayurvedic Medicine Salacia oblonga Attenuates Diabetic Renal Fibrosis in Rats: Suppression of Angiotensin II/AT1 Signaling.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina.

  Journal of human hypertension 20110101

• Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.

  Psychopharmacology 20110101

• Exploration of the binding of benzimidazole-biphenyl derivatives to hemoglobin using docking and molecular dynamics simulation.

  International journal of biological macromolecules 20110101

• Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.

  The Lancet. Neurology 20110101

• Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat.

  American journal of physiology. Heart and circulatory physiology 20110101

• Regulation of posttranscriptional modification as a possible therapeutic approach for retinal neuroprotection.

  Journal of ophthalmology 20110101

• Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101

• Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension.

  The American journal of cardiology 20110101

• Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.

  Clinical drug investigation 20110101

• Effect of telmisartan on the expression of cardiac adiponectin and its receptor 1 in type 2 diabetic rats.

  The Journal of pharmacy and pharmacology 20110101

• Standards of medical care in diabetes--2011.

  Diabetes care 20110101

• Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes.

  International journal of nephrology 20110101

• Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis.

  Journal of Korean medical science 20110101

• Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study.

  Cardiovascular diabetology 20110101

• Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20110101

• Pharmacological and non-pharmacological interventions to influence adipose tissue function.

  Cardiovascular diabetology 20110101

• Effects of asymmetric dimethylarginine on bovine retinal capillary endothelial cell proliferation, reactive oxygen species production, permeability, intercellular adhesion molecule-1, and occludin expression.

  Molecular vision 20110101

• Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats.

  PloS one 20110101

• Improving hypertension control in patients at cardiovascular risk: the case for telmisartan-based therapy.

  Cardiovascular journal of Africa 20110101

• Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal function.

  PloS one 20110101

• Adiponectin provides cardiovascular protection in metabolic syndrome.

  Cardiology research and practice 20110101

• Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management.

  International journal of nephrology 20110101

• A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial.

  Trials 20110101

• Telmisartan in incipient and overt diabetic renal disease.

  Journal of nephrology 20110101

• Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.

  P & T : a peer-reviewed journal for formulary management 20110101

• Renal protection with angiotensin receptor blockers: where do we stand.

  Journal of nephrology 20110101

• Regulation of vascular tone by adipocytes.

  BMC medicine 20110101

• Common secondary causes of resistant hypertension and rational for treatment.

  International journal of hypertension 20110101

• Treatment options for hypertension in high-risk patients.

  Vascular health and risk management 20110101

• Effect of a fat spread enriched with medium-chain triacylglycerols and a special fatty acid-micronutrient combination on cardiometabolic risk factors in overweight patients with diabetes.

  Nutrition & metabolism 20110101

• Olmesartan/amlodipine: a review of its use in the management of hypertension.

  Vascular health and risk management 20110101

• Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.

  BMJ (Clinical research ed.) 20110101

• Affordable hypertension therapy for diabetic patients.

  Cardiovascular journal of Africa 20110101

• Clinical utility of valsartan in the treatment of hypertension in children and adolescents.

  Patient preference and adherence 20110101

• Cardiovascular and Renal Links along the Cardiorenal Continuum.

  International journal of nephrology 20110101

• Microarray evidences the role of pathologic adipose tissue in insulin resistance and their clinical implications.

  Journal of obesity 20110101

• A validated densitometric method for analysis of atorvastatin calcium and metoprolol tartarate as bulk drugs and in combined capsule dosage forms.

  Journal of young pharmacists : JYP 20110101

• Rapid simultaneous determination of telmisartan, amlodipine besylate and hydrochlorothiazide in a combined poly pill dosage form by stability-indicating ultra performance liquid chromatography.

  Scientia pharmaceutica 20110101

• [Clinical- functional assessment of organoprotective efficacy of enalapril and telmisartan in patients with arterial hypertension].

  Kardiologiia 20110101

• Reappraisal of role of angiotensin receptor blockers in cardiovascular protection.

  Vascular health and risk management 20110101

• A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.

  Vascular health and risk management 20110101

• Pleiotropic effects of glitazones: a double edge sword?

  Frontiers in pharmacology 20110101

• Stroke, high blood pressure and the Renin-Angiotensin-aldosterone system - new developments.

  Frontiers in pharmacology 20110101

• Diabetic microvascular complications: possible targets for improved macrovascular outcomes.

  International journal of nephrology and renovascular disease 20110101

• Critical appraisal of irrational drug combinations: A call for awareness in undergraduate medical students.

  Journal of pharmacology & pharmacotherapeutics 20110101

• Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation.

  BMC cancer 20110101

• Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension.

  Indian journal of pharmacology 20110101

• Authors' reply.

  Indian journal of pharmacology 20110101

• New telmisartan/amlodipine single-pill combination offers both efficacy and tolerability.

  Cardiovascular journal of Africa 20110101

• Correlation of intrinsic in vitro and in vivo clearance for drugs metabolized by hepatic UDP-glucuronosyltransferases in rats.

  Drug metabolism and pharmacokinetics 20110101

• Hypertension in chronic kidney disease: navigating the evidence.

  International journal of hypertension 20110101

• Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial).

  International journal of hypertension 20110101

• Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study.

  The open cardiovascular medicine journal 20110101

• Diabetic nephropathy - Epidemiology in Asia and the current state of treatment.

  Indian journal of nephrology 20110101

• Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.

  The open cardiovascular medicine journal 20110101

• Antiplatelets in secondary stroke prevention.

  Frontiers in neurology 20110101

• The Relation between Fructose-Induced Metabolic Syndrome and Altered Renal Haemodynamic and Excretory Function in the Rat.

  International journal of nephrology 20110101

• Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.

  BMJ (Clinical research ed.) 20110101

• Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.

  Vascular health and risk management 20110101

• Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.

  Vascular health and risk management 20110101

• Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.

  Antiviral therapy 20110101

• Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.

  Cardiovascular diabetology 20110101

• Correlation of different NADPH oxidase homologues with late endothelial progenitor cell senescence induced by angiotensin II: effect of telmisartan.

  Internal medicine (Tokyo, Japan) 20110101

• Modeling drug-carrier interaction in the drug release from nanocarriers.

  Journal of drug delivery 20110101

• Genetic polymorphism of ACE and the angiotensin II type1 receptor genes in children with chronic kidney disease.

  Journal of inflammation (London, England) 20110101

• Telmisartan prevents VCAM-1 induction and monocytic cell adhesion to endothelium exposed to non-uniform shear stress and TNF-α.

  Clinical hemorheology and microcirculation 20110101

• Hyperparathyroidism due to eutopic PTH secretion from an ectopic intrathymic parathyroid cyst.

  Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 20110101

• ARBs for cardiovascular and renal protection in high-risk patients.

  Cardiovascular journal of Africa 20110101

• Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models.

  PloS one 20110101

• Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.

  International journal of biological sciences 20110101

• Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension.

  Integrated blood pressure control 20110101

• The effects of simvastatin on left ventricular hypertrophy and left ventricular function in patients with essential hypertension.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20110101

• Anti-albuminuric effects of the angiotensin AT1 receptor blocker telmisartan in hypertensive patients.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20110101

• Quality of online pharmacies and websites selling prescription drugs: a systematic review.

  Journal of medical Internet research 20110101

• Simultaneous determination of related substances of telmisartan and hydrochlorothiazide in tablet dosage form by using reversed phase high performance liquid chromatographic method.

  Journal of pharmacy & bioallied sciences 20110101

• The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.

  Journal of medical economics 20110101

• Inhibition of cardiac sympathetic afferent reflex and sympathetic activity by baroreceptor and vagal afferent inputs in chronic heart failure.

  PloS one 20110101

• Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats.

  Pharmacological reports : PR 20110101

• Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.

  PloS one 20110101

• Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study.

  BMC research notes 20110101

• Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.

  Vascular health and risk management 20110101

• Transforming growth factor β₁ oppositely regulates the hypertrophic and contractile response to β-adrenergic stimulation in the heart.

  PloS one 20110101

• Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method.

  Acta poloniae pharmaceutica 20110101

• Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

  Fibrogenesis & tissue repair 20110101

• Lessons from a mouse model characterizing features of vascular cognitive impairment with white matter changes.

  Journal of aging research 20110101

• Atherogenic ω-6 Lipids Modulate PPAR- EGR-1 Crosstalk in Vascular Cells.

  PPAR research 20110101

• Telmisartan and cardioprotection.

  Vascular health and risk management 20110101

• Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model.

  Experimental diabetes research 20110101

• Prediction of the Human EP1 Receptor Binding Site by Homology Modeling and Molecular Dynamics Simulation.

  Scientia pharmaceutica 20110101

• Zofenopril and incidence of cough: a review of published and unpublished data.

  Therapeutics and clinical risk management 20110101

• Critical review of cancer risk associated with angiotensin receptor blocker therapy.

  Vascular health and risk management 20110101

• Differential clinical profile of candesartan compared to other angiotensin receptor blockers.

  Vascular health and risk management 20110101

• Benefits of once-daily therapies in the treatment of hypertension.

  Vascular health and risk management 20110101

• [State of hepatolienal circulation and liver functions in vibration disease under angioprotector treatment].

  Meditsina truda i promyshlennaia ekologiia 20110101

• Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

  Integrated blood pressure control 20110101

• Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator.

  Nephron extra 20110101

• In vivo bioavailability studies of sumatriptan succinate buccal tablets.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Renoprotective effects of combining ACE inhibitors and statins in experimental diabetic rats.

  Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

• Angiotensin II, a Neuropeptide at the Frontier between Endocrinology and Neuroscience: Is There a Link between the Angiotensin II Type 2 Receptor and Alzheimer's Disease?

  Frontiers in endocrinology 20110101

• Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.

  Bioorganic & medicinal chemistry 20101215

• The effects of telmisartan on mechanical responses of left ventricular papillary muscle in rats with streptozotocin-induced diabetes mellitus.

  Acta diabetologica 20101201

• Significant hyperkalemia and hyponatremia secondary to telmisartan/hydrochlorothiazide treatment.

  Blood pressure 20101201

• Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartan-hydrochlorothiazide.

  Cutaneous and ocular toxicology 20101201

• Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease.

  Clinical research in cardiology : official journal of the German Cardiac Society 20101201

• Left ventricular hypertrophy induced by abdominal aortic banding and its prevention by angiotensin receptor blocker telmisartan--a proteomic analysis.

  Journal of physiology and biochemistry 20101201

• Regression of target organ damage in children and adolescents with primary hypertension.

  Pediatric nephrology (Berlin, Germany) 20101201

• p63RhoGEF--a key mediator of angiotensin II-dependent signaling and processes in vascular smooth muscle cells.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20101201

• Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance.

  The Journal of pharmacology and experimental therapeutics 20101201

• The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

  Rheumatology (Oxford, England) 20101201

• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Impact of RGS2 deficiency on the therapeutic effect of telmisartan in angiotensin II-induced aortic aneurysm.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101201

• Substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonist: a review.

  Mini reviews in medicinal chemistry 20101201

• Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20101201

• The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20101201

• Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats.

  The Journal of pharmacy and pharmacology 20101201

• Responses of human endothelial cells to pathogenic and non-pathogenic Leptospira species.

  PLoS neglected tropical diseases 20101201

• [Markers of endothelial function in the early stages of essential hypertension and the effect of antihypertensive therapy].

  Vnitrni lekarstvi 20101201

• Delayed intrathyroidal hematoma causing respiratory distress after a seemingly benign fall: a case report.

  International journal of emergency medicine 20101201

• Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet.

  International journal of emergency medicine 20101201

• Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.

  Journal of the American College of Cardiology 20101116

• Treating heart failure on dialysis. Finally getting some evidence.

  Journal of the American College of Cardiology 20101116

• [Fixed combination of telmisartan and amlodipine. Lowering blood pressure with dual power].

  MMW Fortschritte der Medizin 20101104

• Identification and characterization of a photolytic degradation product of telmisartan using LC-MS/TOF, LC-MSn, LC-NMR and on-line H/D exchange mass studies.

  Journal of pharmaceutical and biomedical analysis 20101102

• Combined effect of polarity and pH on the chromatographic behavior of some angiotensin II receptor antagonists and optimization of their determination in pharmaceutical dosage forms.

  Journal of pharmaceutical and biomedical analysis 20101102

• [Effect of telmisartan on tubulointerstitial injury and expression of PPARγ in rat renal tissue of IgA nephropathy model].

  Zhonghua yi xue za zhi 20101102

• Diagnosis of early myocarditis after respiratory or gastrointestinal tract viral infection: insights from cardiovascular magnetic resonance.

  Clinical research in cardiology : official journal of the German Cardiac Society 20101101

• Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice.

  Laboratory investigation; a journal of technical methods and pathology 20101101

• Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together?

  Current vascular pharmacology 20101101

• The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus.

  Current cardiology reports 20101101

• Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database.

  Journal of hypertension 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril.

  Heart and vessels 20101101

• Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results.

  Expert review of cardiovascular therapy 20101101

• Strategies for initial management of hypertension.

  The Indian journal of medical research 20101101

• [The role of renin-angiotensin system independent angiotensin II production in progression and fibrosis of intrahepatic cholangiocarcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• [INNOVATION study].

  Nihon rinsho. Japanese journal of clinical medicine 20101101

• Simple, sensitive and rapid HPLC-MS/MS method for the determination of cepharanthine in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101015

• Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels.

  Journal of cellular and molecular medicine 20101001

• Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20101001

• Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose.

  European journal of endocrinology 20101001

• Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension.

  Clinical pediatrics 20101001

• Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan.

  International journal of molecular medicine 20101001

• Differential susceptibility to epithelial-mesenchymal transition (EMT) of alveolar, bronchial and intestinal epithelial cells in vitro and the effect of angiotensin II receptor inhibition.

  Cell and tissue research 20101001

• Left atrial appendage thrombus detected by intraoperative transesophageal echocardiography in a patient with acute small bowel infarction -A case report-.

  Korean journal of anesthesiology 20101001

• Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia.

  Brain research 20100924

• Possible mechanisms of left ventricular torsion evaluated by cardioreparative effects of telmisartan in patients with hypertension.

  European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 20100901

• Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.

  Antimicrobial agents and chemotherapy 20100901

• Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.

  European journal of clinical investigation 20100901

• Have we fallen off target with concerns surrounding dual RAAS blockade?

  Kidney international 20100901

• Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.

  Current medical research and opinion 20100901

• Inclusion of telmisartan in mesocellular foam nanoparticles: drug loading and release property.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100901

• Cutting through the statistical fog: understanding and evaluating non-inferiority trials.

  International journal of clinical practice 20100901

• Effectiveness, safety and cost of drug substitution in hypertension.

  British journal of clinical pharmacology 20100901

• Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion.

  British journal of pharmacology 20100901

• Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment.

  American heart journal 20100901

• Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20100901

• Drug synergism of antihypertensive action in combination of telmisartan with lercanidipine in spontaneous hypertensive rats.

  Archives of pharmacal research 20100901

• Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.

  European journal of pharmacology 20100825

• Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode.

  Bioorganic & medicinal chemistry 20100815

• Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan.

  Journal of controlled release : official journal of the Controlled Release Society 20100803

• Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.

  Metabolism: clinical and experimental 20100801

• Longitudinal changes in central artery stiffness with lifestyle modification, washout, and drug treatment in individuals at risk for cardiovascular disease.

  Metabolic syndrome and related disorders 20100801

• Telmisartan improves morphologic and functional changes in both left ventricular myocardium and carotid arterial wall in patients with hypertension: assessment by tissue Doppler imaging and carotid ultrasonography.

  Echocardiography (Mount Kisco, N.Y.) 20100801

• Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.

  Journal of hypertension 20100801

• Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.

  Current diabetes reports 20100801

• Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100801

• Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion.

  Stroke 20100801

• Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension.

  Blood pressure monitoring 20100801

• High-risk patients benefit most from nifedipine GITS-telmisartan combination.

  Cardiovascular journal of Africa 20100801

• [Comprehensive management of cardiovascular risk. Focusing on telmisartan].

  Vnitrni lekarstvi 20100801

• [Aortic pulse wave velocity in patients with metabolic syndrome and hypertension treated with sartans].

  Vnitrni lekarstvi 20100801

• [Effects of telmisartan on 4-Aminopyridine-sensitive voltage dependant potassium channel of lymphocyte derived from spontaneously hypertensive rat].

  Zhonghua xin xue guan bing za zhi 20100801

• Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels.

  Clinical science (London, England : 1979) 20100723

• Ameliorative effects of telmisartan in diabetic rats with indomethacin-induced gastric ulceration.

  European journal of pharmacology 20100710

• Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

  Drugs 20100709

• Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats.

  Bone 20100701

• Salt supplementation blunts the blood pressure response to telmisartan with or without hydrochlorothiazide in hypertensive patients with type 2 diabetes.

  Diabetologia 20100701

• Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties.

  Expert opinion on drug metabolism & toxicology 20100701

• Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100701

• Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

  The Lancet. Oncology 20100701

• Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: is less really more?

  Journal of hypertension 20100701

• A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.

  Hepatology (Baltimore, Md.) 20100701

• Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat.

  Journal of hypertension 20100701

• Relationship between serum uric Acid levels, metabolic syndrome, and arterial stiffness in korean.

  Korean circulation journal 20100701

• Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.

  The Indian journal of medical research 20100701

• Fixed-dose telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients.

  International heart journal 20100701

• Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia.

  Brain research 20100622

• Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.

  Clinical science (London, England : 1979) 20100608

• Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells.

  Journal of cellular and molecular medicine 20100601

• Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study.

  Atherosclerosis 20100601

• Angiotensin II enhances interleukin-1 beta-induced MMP-9 secretion in adult rat cardiac fibroblasts.

  The Journal of veterinary medical science 20100601

• Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more.

  Clinical research in cardiology : official journal of the German Cardiac Society 20100601

• A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.

  Pharmacogenetics and genomics 20100601

• Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction.

  Journal of hypertension 20100601

• Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.

  European journal of internal medicine 20100601

• A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20100601

• [The normalized smoothness index and parametric population RDH index of telmisartane in patients with newly diagnosed hypertension and metabolic syndrome].

  Vnitrni lekarstvi 20100601

• Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension.

  Indian journal of pharmacology 20100601

• Colloid formation by drugs in simulated intestinal fluid.

  Journal of medicinal chemistry 20100527

• Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes.

  Chemico-biological interactions 20100514

• Treatment with telmisartan attenuates graft arteriosclerosis in murine cardiac allografts.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20100501

• Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes.

  Diabetologia 20100501

• Measurement of adiponectin production from differentiated metabolic stem cells.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100501

• Improvement of coronary flow velocity reserve with telmisartan in patients with autosomal-dominant polycystic kidney disease.

  Southern medical journal 20100501

• Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment.

  Diabetes technology & therapeutics 20100501

• Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients.

  Heart and vessels 20100501

• Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension.

  Drugs of today (Barcelona, Spain : 1998) 20100501

• Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension.

  Chronobiology international 20100501

• The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

  Current cardiology reviews 20100501

• Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy.

  Chemico-biological interactions 20100429

• Citrus limetta leaves extract antagonizes the hypertensive effect of angiotensin II.

  Journal of ethnopharmacology 20100421

• Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation.

  Journal of molecular modeling 20100401

• Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100401

• Appropriateness of timing of drug administration in electronic prescriptions.

  Pharmacy world & science : PWS 20100401

• Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension.

  Current medical research and opinion 20100401

• Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways.

  Hypertension (Dallas, Tex. : 1979) 20100401

• Simultaneous analysis of isomers of escin saponins in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100401

• Impairment of renal function in a patient with IgA deficiency-associated mesangioproliferative glomerulonephritis.

  Clinical nephrology 20100401

• Application of direct renin inhibition to chronic kidney disease.

  Cardiovascular drugs and therapy 20100401

• Determining the structural relaxation times deep in the glassy state of the pharmaceutical Telmisartan.

  Journal of physics. Condensed matter : an Institute of Physics journal 20100331

• Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.

  Circulation 20100330

• Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance.

  International journal of cardiology 20100318

• Protective effects of telmisartan on ischemia/reperfusion injury of rat ovary: biochemical and histopathologic evaluation.

  Fertility and sterility 20100301

• Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.

  The Journal of pharmacology and experimental therapeutics 20100301

• HIVAN phenotype: consequence of epithelial mesenchymal transdifferentiation.

  American journal of physiology. Renal physiology 20100301

• Blood pressure and diabetic nephropathy.

  Diabetes care 20100301

• Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease.

  International journal of clinical pharmacology and therapeutics 20100301

• Review of the AMADEO study: reducing proteinuria in patients with diabetic nephropathy with telmisartan versus losartan. Commentary.

  Postgraduate medicine 20100301

• Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.

  Biopharmaceutics & drug disposition 20100301

• Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.

  Clinical therapeutics 20100301

• New data on ONTARGET: more confusion?

  Journal of clinical hypertension (Greenwich, Conn.) 20100301

• The effect of Telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells.

  European journal of pharmacology 20100225

• [Positive added effect of telmisartan. New therapy alternative for a large collection of cardiovascular risk patients].

  MMW Fortschritte der Medizin 20100225

• Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.

  Bioorganic & medicinal chemistry letters 20100215

• Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.

  Journal of medicinal chemistry 20100211

• alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy.

  Journal of molecular medicine (Berlin, Germany) 20100201

• Sensitization to alloxan-induced diabetes and pancreatic cell apoptosis in acatalasemic mice.

  Biochimica et biophysica acta 20100201

• Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100201

• eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.

  The American journal of pathology 20100201

• Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.

  The Annals of pharmacotherapy 20100201

• Renoprotective effects of telmisartan in patients with advanced chronic kidney disease.

  Clinical nephrology 20100201

• In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats.

  Microcirculation (New York, N.Y. : 1994) 20100201

• Evaluation of blockbuster drugs under the rule-of-five.

  Die Pharmazie 20100201

• Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.

  Cardiovascular drugs and therapy 20100201

• [Renal effects of combined anti-hypertensive treatments].

  Recenti progressi in medicina 20100201

• Adverse drug reaction monitoring with angiotensin converting enzyme inhibitors: A prospective, randomized, open-label, comparative study.

  Indian journal of pharmacology 20100201

• [LC-MS/MS method for simultaneous quantification of lopinavir and ritonavir in human plasma].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100201

• A third amlodipine/ARB combination (Twynsta) for hypertension.

  The Medical letter on drugs and therapeutics 20100111

• Cardiovascular disease risk factors: epidemiology and risk assessment.

  The American journal of cardiology 20100104

• Are there effects of renin-angiotensin system antagonists beyond blood pressure control?

  The American journal of cardiology 20100104

• Renin-angiotensin system blockade and cardiovascular and renal protection.

  The American journal of cardiology 20100104

• Telmisartan in high-risk cardiovascular patients.

  The American journal of cardiology 20100104

• Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.

  Life sciences 20100102

• Telmisartan and metabolic syndrome after heart transplantation.

  Clinical transplantation 20100101

• Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis.

  Basic research in cardiology 20100101

• High-salt diet increases plasma adiponectin levels independent of blood pressure in hypertensive rats: the role of the renin-angiotensin-aldosterone system.

  Journal of hypertension 20100101

• The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial.

  Journal of hypertension 20100101

• Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.

  Metabolism: clinical and experimental 20100101

• Is therapy of people with chronic kidney disease ONTARGET?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100101

• Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors.

  Biochemical and biophysical research communications 20100101

• Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.

  Current medical research and opinion 20100101

• ONTARGET should not be over interpreted.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100101

• Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?

  Future cardiology 20100101

• Usefulness of RAS inhibition depends on baseline albuminuria.

  Nature reviews. Nephrology 20100101

• PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis.

  Acta pharmacologica Sinica 20100101

• Standards of medical care in diabetes--2010.

  Diabetes care 20100101

• Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20100101

• Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.

  BMJ (Clinical research ed.) 20100101

• Angiotensin II receptor expression and relation to Helicobacter pylori-infection in the stomach of the Mongolian gerbil.

  BMC gastroenterology 20100101

• New drug information: Twynsta 40 mg/5mg.

  JAAPA : official journal of the American Academy of Physician Assistants 20100101

• Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

• Nephroprotective effect of telmisartan in rats with ischemia/reperfusion renal injury.

  Pharmacology 20100101

• Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.

  Clinical therapeutics 20100101

• Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care.

  Vascular health and risk management 20100101

• Modern role for clopidogrel in management of atrial fibrillation and stroke reduction.

  Vascular health and risk management 20100101

• Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan.

  Journal of pharmacological sciences 20100101

• Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients.

  Arzneimittel-Forschung 20100101

• Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.

  PloS one 20100101

• Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms.

  PloS one 20100101

• Aquaporin expression in blood-retinal barrier cells during experimental autoimmune uveitis.

  Molecular vision 20100101

• The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788].

  Implementation science : IS 20100101

• Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention.

  Annals of Indian Academy of Neurology 20100101

• The role of renin angiotensin system inhibition in kidney repair.

  Fibrogenesis & tissue repair 20100101

• New standards in hypertension and cardiovascular risk management: focus on telmisartan.

  Vascular health and risk management 20100101

• Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients.

  Nutricion hospitalaria 20100101

• The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone.

  Internal medicine (Tokyo, Japan) 20100101

• The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study.

  Cardiovascular diabetology 20100101

• Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report.

  Journal of medical case reports 20100101

• The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.

  Mediators of inflammation 20100101

• Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.

  Acta clinica Belgica 20100101

• Efficient and improved synthesis of Telmisartan.

  Beilstein journal of organic chemistry 20100101

• Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages.

  Mediators of inflammation 20100101

• HIV protease inhibitors activate the adipocyte renin angiotensin system.

  Antiviral therapy 20100101

• Use of evidence-based pharmacotherapy after myocardial infarction in Estonia.

  BMC public health 20100101

• Combination therapy in hypertension: An update.

  Diabetology & metabolic syndrome 20100101

• Functional polymorphisms in genes of the Angiotensin and Serotonin systems and risk of hypertrophic cardiomyopathy: AT1R as a potential modifier.

  Journal of translational medicine 20100101

• PPARs in the Renal Regulation of Systemic Blood Pressure.

  PPAR research 20100101

• Influence of cyclodextrin complexation with NSAIDs on NSAID/cold stress-induced gastric ulceration in rats.

  International journal of medical sciences 20100101

• Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.

  Journal of ophthalmology 20100101

• Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway.

  Mediators of inflammation 20100101

• Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients.

  Kidney & blood pressure research 20100101

• The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents.

  Clinical hemorheology and microcirculation 20100101

• Foreign body ingestion mimicking irritable bowel syndrome: a case report.

  Journal of medical case reports 20100101

• Advanced glycation end products, oxidative stress and diabetic nephropathy.

  Oxidative medicine and cellular longevity 20100101

• Ang II enhances tubular cell Ets-1 expression and associated down stream signaling is mediated through AT1 receptors.

  Renal failure 20100101

• Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.

  Vascular health and risk management 20100101

• Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

  Vascular health and risk management 20100101

• Therapeutic Implications of PPARgamma in Cardiovascular Diseases.

  PPAR research 20100101

• Effects of captopril and telmisartan on matrix metalloproteinase-2 and -9 expressions and development of left ventricular fibrosis induced by isoprenaline in rats.

  Biological & pharmaceutical bulletin 20100101

• Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.

  Internal medicine (Tokyo, Japan) 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Aliskiren and valsartan combination therapy for the management of hypertension.

  Vascular health and risk management 20100101

• Role of endothelin receptor A and NADPH oxidase in vascular abnormalities.

  Vascular health and risk management 20100101

• Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury.

  Renal failure 20100101

• Health technology assessment review: remote monitoring of vital signs--current status and future challenges.

  Critical care (London, England) 20100101

• Renal protection in diabetes: lessons from ONTARGET.

  Cardiovascular diabetology 20100101

• Telmisartan and obesity.

  Internal medicine (Tokyo, Japan) 20100101

• Recent advances in the management of hypertension.

  F1000 medicine reports 20100101

• PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice.

  Cardiovascular diabetology 20100101

• New class of agents for treatment of hypertension: focus on direct renin inhibition.

  Vascular health and risk management 20100101

• From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.

  Cardiology 20100101

• Risk assessment and aspirin use in Asian and Western populations.

  Vascular health and risk management 20100101

• Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis.

  BMC nephrology 20100101

• Angiotensin-converting enzyme inhibitors will not help in improving stroke outcome if given immediately after stroke.

  Annals of Indian Academy of Neurology 20100101

• Telmisartan/amlodipine: single-pill combination in hypertension.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).

  Oxidative medicine and cellular longevity 20100101

• Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension.

  Oxidative medicine and cellular longevity 20100101

• Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.

  Clinical interventions in aging 20100101

• Where does the evidence lead us for the proper use of angiotensin II inhibitors in the management of cardiovascular disease?

  Cardiology 20100101

• Simultaneous quantitative determination of metoprolol, atorvastatin and ramipril in capsules by a validated stability-indicating RP-UPLC method.

  Scientia pharmaceutica 20100101

• Cardio classics revisited--focus on the role of candesartan.

  Vascular health and risk management 20100101

• In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.

  PloS one 20100101

• Design and optimization of a chemometric-assisted spectrophotometric determination of telmisartan and hydrochlorothiazide in pharmaceutical dosage form.

  Journal of young pharmacists : JYP 20100101

• Effect of PPARγ inhibition during pregnancy on posterior cerebral artery function and structure.

  Frontiers in physiology 20100101

• Effect of Holostemma annularis on the progression of diabetes induced by a high fructose diet in rats and in diabetic C57BL/6J ob/ob mice.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Renovascular and renoprotective properties of telmisartan: clinical utility.

  International journal of nephrology and renovascular disease 20100101

• Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment.

  International journal of nephrology and renovascular disease 20100101

• Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

  International journal of nephrology and renovascular disease 20100101

• Management of amlodipine-induced gingival enlargement: Series of three cases.

  Journal of Indian Society of Periodontology 20100101

• Evidence-based approach for managing hypertension in type 2 diabetes.

  Integrated blood pressure control 20100101

• Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction.

  Integrated blood pressure control 20100101

• Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals.

  Integrated blood pressure control 20100101

• Impact of telmisartan in modifying vascular risk.

  Integrated blood pressure control 20100101

• Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals.

  Integrated blood pressure control 20100101

• Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control.

  Integrated blood pressure control 20100101

• Cardiovascular risk reduction with Renin-Angiotensin aldosterone system blockade.

  Nursing research and practice 20100101

• Very high central aortic systolic pressures in a young hypertensive patient on telmisartan: Is central aortic systolic pressure associated with white coat hypertension?

  The International journal of angiology : official publication of the International College of Angiology, Inc 20100101

• Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.

  Journal of human hypertension 20091201

• Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A(2) level in experimental stroke.

  Journal of neurotrauma 20091201

• Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20091201

• PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy.

  Experimental eye research 20091201

• An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice.

  The Journal of pharmacology and experimental therapeutics 20091201

• Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.

  Hypertension (Dallas, Tex. : 1979) 20091201

• Telmisartan prevents cardiovascular events in a broad group of at-risk patients.

  Expert opinion on pharmacotherapy 20091201

• Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).

  The American journal of cardiology 20091201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091201

• Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients.

  Journal of clinical pharmacy and therapeutics 20091201

• Drug repositioning using in silico compound profiling.

  Future medicinal chemistry 20091201

• Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition.

  Clinical science (London, England : 1979) 20091116

• Is telmisartan effective for stroke prevention?

  American family physician 20091115

• Molecular mobility in liquid and glassy states of telmisartan (TEL) studied by broadband dielectric spectroscopy.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20091105

• Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity.

  Pharmacological research 20091101

• Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells.

  Diabetes & metabolism 20091101

• Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.

  Hypertension research : official journal of the Japanese Society of Hypertension 20091101

• Rapid determination of telmisartan in human plasma by HPLC using a monolithic column with fluorescence detection and its application to a bioequivalence study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101

• Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS subgroup analysis.

  Stroke 20091101

• Hypertension and diabetes: should we treat early surrogates? What are the cons?

  Diabetes care 20091101

• Dual blockade of the renin-angiotensin system in diabetic nephropathy.

  Diabetes care 20091101

• [Intestinal absorption and secretion mechanism of carboxylate drugs].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20091101

• Constitutively active mutant N111G of angiotensin II type 1 (AT(1)) receptor induces homologous internalization through mediation of AT(1)-receptor antagonist.

  Journal of pharmacological sciences 20091101

• Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.

  Expert review of cardiovascular therapy 20091101

• Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study.

  Transplantation proceedings 20091101

• Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20091101

• Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism.

  Neuroscience letters 20091030

• Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

  Circulation 20091006

• Effects of AT1- and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice.

  European journal of clinical investigation 20091001

• Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statin-treated hypertensive hypercholesterolemic patients.

  Fundamental & clinical pharmacology 20091001

• Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.

  Diabetes care 20091001

• Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.

  Molecular & cellular proteomics : MCP 20091001

• Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.

  Hypertension (Dallas, Tex. : 1979) 20091001

• Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction.

  European journal of pharmacology 20091001

• Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.

  Hypertension (Dallas, Tex. : 1979) 20091001

• Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs.

  American journal of hypertension 20091001

• Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.

  Bioorganic & medicinal chemistry 20091001

• Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?

  Current hypertension reports 20091001

• Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats.

  Journal of pharmacological sciences 20091001

• Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.

  Clinical therapeutics 20091001

• [Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].

  Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 20091001

• [Perindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertension].

  Zhonghua xin xue guan bing za zhi 20091001

• Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine.

  Journal of the Indian Medical Association 20091001

• Determination of losartan, telmisartan, and valsartan by direct injection of human urine into a column-switching liquid chromatographic system with fluorescence detection.

  Journal of pharmaceutical and biomedical analysis 20090908

• Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.

  Journal of human hypertension 20090901

• Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model.

  Atherosclerosis 20090901

• Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial.

  Cephalalgia : an international journal of headache 20090901

• The protective role of telmisartan against nephrotoxicity induced by X-ray contrast media in rat model.

  Acta radiologica (Stockholm, Sweden : 1987) 20090901

• Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging.

  Journal of hypertension 20090901

• The role of transporters in the pharmacokinetics of orally administered drugs.

  Pharmaceutical research 20090901

• Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090901

• Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090901

• Lessons learned from the ONTARGET and TRANSCEND trials.

  Current atherosclerosis reports 20090901

• AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.

  Translational research : the journal of laboratory and clinical medicine 20090901

• Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

  Expert review of neurotherapeutics 20090901

• Gastroprotective effects of telmisartan on experimentally-induced gastric ulcers in rats.

  Die Pharmazie 20090901

• A case report of prenatal exposure to rosuvastatin and telmisartan.

  Paediatrics & child health 20090901

• [Erectile dysfunction as a harbinger of cardiovascular events. Long-term vascular protection with telmisartan].

  MMW Fortschritte der Medizin 20090820

• Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway.

  Atherosclerosis 20090801

• Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.

  Liver international : official journal of the International Association for the Study of the Liver 20090801

• Reduction in urinary excretion of neutrophil gelatinase-associated lipocalin by angiotensin receptor blockers in hypertensive patients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090801

• Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.

  Diabetes care 20090801

• The role of peroxisome proliferator-activated receptor gamma in blood pressure regulation.

  Current hypertension reports 20090801

• Proteinuria: Is the ONTARGET renal substudy actually off target?

  Nature reviews. Nephrology 20090801

• [Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese Hypertension Intervention Efficacy (CHIEF) trial].

  Zhonghua xin xue guan bing za zhi 20090801

• Telmisartan did not prevent renal disease in patients without proteinuria.

  Annals of internal medicine 20090707

• Effect of telmisartan on renal outcomes: a randomized trial.

  Annals of internal medicine 20090707

• The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.

  Clinical research in cardiology : official journal of the German Cardiac Society 20090701

• Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes?

  European journal of pharmacology 20090701

• Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090701

• Characterization of new PPARgamma agonists: benzimidazole derivatives - the importance of position 2.

  ChemMedChem 20090701

• Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.

  Journal of hypertension 20090701

• Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090701

• Effects of angiotensin II receptor blockers on diabetic nephropathy.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090701

• Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090701

• Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090701

• Cardiovascular protection: a breakthrough for high-risk patients?

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090701

• Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090701

• Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension.

  International heart journal 20090701

• Use of angiotensin receptor blockers after angioedema with an angiotensin-converting enzyme inhibitor.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20090701

• Strain-dependent differences of restraint stress-induced hypertension in WKY and SHR.

  Physiology & behavior 20090622

• Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.

  The Journal of pharmacology and experimental therapeutics 20090601

• Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes.

  Diabetes 20090601

• Deletion of angiotensin II type I receptor reduces hepatic steatosis.

  Journal of hepatology 20090601

• Understanding the PRoFESS Study for Secondary Stroke Prevention.

  Current treatment options in cardiovascular medicine 20090601

• Angiotensin II stimulates MCP-1 production in rat glomerular endothelial cells via NAD(P)H oxidase-dependent nuclear factor-kappa B signaling.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20090601

• Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome.

  The American journal of cardiology 20090601

• ONTARGET: use of ramipril, telmisartan, or both in patients with high cardiovascular risks.

  Current diabetes reports 20090601

• How to achieve renal protection in the light of ONTARGET?

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090601

• Practical aspects of treatment discontinuation and adherence.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090601

• Main results and clinical interpretations from the TRANSCEND study.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090601

• Prevention of major cardiovascular events with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker early or late after stroke.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090601

• The question of heart failure in ONTARGET and TRANSCEND: implications for clinical practice.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090601

• ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090601

• Implementation of new evidence into hypertension guidelines: the case of the ONTARGET and TRANSCEND trials.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090601

• Focus on the ONTARGET results.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20090601

• Blocking the renin-angiotensin system: dual- versus mono-therapy.

  Expert review of cardiovascular therapy 20090601

• [Effects of Songling Xuemaikang Capsule on ambulatory blood pressure in treatment of essential hypertension: a single-blind randomized controlled trial].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20090601

• Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.

  Journal of human hypertension 20090501

• PRoFESS.

  Stroke 20090501

• Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?

  Stroke 20090501

• Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.

  Investigative ophthalmology & visual science 20090501

• Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.

  Hypertension (Dallas, Tex. : 1979) 20090501

• Telmisartan, an angiotensin II type 1 receptor antagonist, attenuates T-type Ca2+ channel expression in neonatal rat cardiomyocytes.

  European journal of pharmacology 20090501

• Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20090501

• Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.

  International journal of clinical practice 20090501

• Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090501

• The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension.

  Korean circulation journal 20090501

• Antihypertensive therapy, new-onset diabetes, and cardiovascular disease.

  International journal of clinical practice 20090401

• Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20090401

• Telmisartan did not prevent recurrent stroke or major cardiovascular events.

  Evidence-based medicine 20090401

• Chronic production of peroxynitrite in the vascular wall impairs vasorelaxation function in SHR/NDmcr-cp rats, an animal model of metabolic syndrome.

  Journal of pharmacological sciences 20090401

• [Large clinical trials of ARB in Japan and its reflection to new guidelines].

  Nihon rinsho. Japanese journal of clinical medicine 20090401

• Clinical practice guides.

  Clinical cardiology 20090401

• Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity.

  Journal of atherosclerosis and thrombosis 20090401

• Results of treatment with telmisartan-amlodipine in hypertensive patients.

  Journal of clinical hypertension (Greenwich, Conn.) 20090401

• Questioning the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting.

  The Physician and sportsmedicine 20090401

• Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials.

  Lancet (London, England) 20090321

• [A new possible strategy for prevention and preventive treatment of age-related macular degeneration resting on recent clinical and pathophysiological observations].

  Orvosi hetilap 20090315

• Interactions of glucose metabolism and chronic heart failure.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20090301

• Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats.

  American journal of physiology. Regulatory, integrative and comparative physiology 20090301

• Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20090301

• Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.

  Diabetes research and clinical practice 20090301

• Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats.

  European journal of pharmacology 20090301

• Characterization of new PPARgamma agonists: analysis of telmisartan's structural components.

  ChemMedChem 20090301

• Telmisartan increases the permeability of endothelial cells through zonula occludens-1.

  Biological & pharmaceutical bulletin 20090301

• Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20090301

• Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study.

  Postgraduate medicine 20090301

• Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?

  Postgraduate medicine 20090301

• Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary.

  Postgraduate medicine 20090301

• Nebivolol: a third-generation beta-blocker for hypertension.

  Clinical therapeutics 20090301

• Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.

  World journal of gastroenterology 20090227

• ACP Journal Club. Telmisartan did not reduce a composite of CV death, MI, HF, or stroke in high-risk patients intolerant to ACE inhibitors.

  Annals of internal medicine 20090217

• ACP Journal Club. Telmisartan did not prevent recurrent stroke or major cardiovascular events.

  Annals of internal medicine 20090217

• The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.

  Journal of the American College of Cardiology 20090210

• Telmisartan in high-risk patients intolerant of ACE inhibitors.

  Lancet (London, England) 20090207

• Telmisartan in high-risk patients intolerant of ACE inhibitors.

  Lancet (London, England) 20090207

• Telmisartan in high-risk patients intolerant of ACE inhibitors.

  Lancet (London, England) 20090207

• Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril.

  International journal of cardiology 20090206

• Editorial comment on: Bladder angiotensin-II receptors: characterization and alteration in bladder outlet obstruction.

  European urology 20090201

• Bladder angiotensin-II receptors: characterization and alteration in bladder outlet obstruction.

  European urology 20090201

• Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan.

  American journal of physiology. Renal physiology 20090201

• High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090201

• Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20090201

• ONTARGET: How much RAS inhibition is enough?

  Current hypertension reports 20090201

• A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.

  Endocrinology 20090201

• A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes.

  Evidence-based medicine 20090201

• Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication.

  Expert opinion on pharmacotherapy 20090201

• [The ONTARGET trial].

  Giornale italiano di cardiologia (2006) 20090201

• [The strange story of the Sherpa and the tank of carbon monoxide: that is the story of a scientific adventure. A HIGHCARE 2008 substudy].

  Giornale italiano di cardiologia (2006) 20090201

• [Effects of telmisartan on voltage-gated Kv1.3 and Kv1.5 potassium channels expressed in Xenopus oocytes].

  Zhonghua xin xue guan bing za zhi 20090201

• 4-Methyl-2-n-propyl-1H-benzimidazole-6-carboxylic acid.

  Acta crystallographica. Section E, Structure reports online 20090201

• Telmisartan for prevention of cardiovascular events.

  The New England journal of medicine 20090115

• Telmisartan for prevention of cardiovascular events.

  The New England journal of medicine 20090115

• Telmisartan for prevention of cardiovascular events.

  The New England journal of medicine 20090115

• Telmisartan pharmacokinetics in Japanese renal transplant recipients.

  Clinica chimica acta; international journal of clinical chemistry 20090101

• Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease.

  Nature clinical practice. Nephrology 20090101

• Increased transient receptor potential canonical type 3 channels in vasculature from hypertensive rats.

  Hypertension (Dallas, Tex. : 1979) 20090101

• Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.

  Diabetes research and clinical practice 20090101

• No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects.

  Clinical chemistry and laboratory medicine 20090101

• Telmisartan is more effective than losartan in reducing proteinuria.

  Kidney international 20090101

• Standards of medical care in diabetes--2009.

  Diabetes care 20090101

• Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways.

  PPAR research 20090101

• Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats.

  Canadian journal of physiology and pharmacology 20090101

• Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients.

  Chronobiology international 20090101

• Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?

  Blood pressure 20090101

• Telmisartan in daily clinical practice: factors affecting efficacy in treatment of primary arterial hypertension.

  Journal of postgraduate medicine 20090101

• Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function.

  International heart journal 20090101

• Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension.

  International heart journal 20090101

• Protecting the health of patients at cardiovascular and cerebrovascular risk - Boehringer-Ingelheim's South African journey: from fibrinolytics (Actilyse and Metalyse) to the protective anti-hypertensive (Micardis).

  Cardiovascular journal of Africa 20090101

• Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.

  Preventive cardiology 20090101

• Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.

  Cardiovascular diabetology 20090101

• Analysis of published economic evaluations of angiotensin receptor blockers.

  Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20090101

• Angiotensin-receptor blockers in prevention of cardiovascular events: are they as effective as angiotensin-converting enzyme inhibitors?

  Polskie Archiwum Medycyny Wewnetrznej 20090101

• Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation.

  Drug metabolism and drug interactions 20090101

• The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies.

  Mediators of inflammation 20090101

• Recent advances in cardiovascular risk reduction: implications of ONTARGET.

  Clinical cornerstone 20090101

• Results of the ONTARGET and TRANSCEND studies: an update and discussion.

  Vascular health and risk management 20090101

• The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man.

  Vascular health and risk management 20090101

• Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.

  Vascular health and risk management 20090101

• Effects of cardiovascular angiotensin II type 1 receptor blockade on nitric oxide synthase inhibition in patients with insulin resistance syndrome.

  Blood pressure 20090101

• [Modern tendencies in the treatment of patients with high risk of development of cardiovascular complications and intolerance to angiotensin converting enzyme inhibitors: value of results of TRANSCEND trial for clinical practice].

  Kardiologiia 20090101

• Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

  Vascular health and risk management 20090101

• Impact of statins and ACE inhibitors on mortality after COPD exacerbations.

  Respiratory research 20090101

• Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.

  Advances in medical sciences 20090101

• Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution.

  Nephron. Clinical practice 20090101

• A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention.

  Vascular health and risk management 20090101

• Are the pleiotropic effects of telmisartan clinically relevant?

  Current pharmaceutical design 20090101

• Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin.

  PloS one 20090101

• Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

  PPAR research 20090101

• Need for new hypertension guidelines for high-risk patients.

  Cardiovascular journal of Africa 20090101

• A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.

  Therapeutics and clinical risk management 20090101

• Cardiovascular disease in patients with chronic kidney disease.

  Vascular health and risk management 20090101

• Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.

  Vascular health and risk management 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Beneficial effects of telmisartan in an HIV+ diabetic insulin-dependent patient.

  International journal of immunopathology and pharmacology 20090101

• Diabetic nephropathy.

  Diabetology & metabolic syndrome 20090101

• Severe hypokalemia, metabolic alkalosis and hypertension in a 54 year old male with ectopic ACTH syndrome: a case report.

  Cases journal 20090101

• The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly.

  Archives of gerontology and geriatrics 20090101

• Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis.

  International archives of medicine 20090101

• Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?

  Journal of the American Board of Family Medicine : JABFM 20090101

• Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.

  Vascular health and risk management 20090101

• Early and effective treatment of hypertension: ONTARGET provides some answers.

  Cardiovascular journal of Africa 20090101

• Comparative assessment of angiotensin receptor blockers in different clinical settings.

  Vascular health and risk management 20090101

• [Arterial hypertension and type 2 diabetes mellitus: clinical evaluation of hemodynamic characteristics, possibility of correction].

  Klinicheskaia meditsina 20090101

• Retinal phototoxicity in a novel murine model of intraocular lens implantation.

  Molecular vision 20090101

• Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.

  Vascular health and risk management 20090101

• Telmisartan: a different angiotensin II receptor blocker protecting a different population?

  The Journal of international medical research 20090101

• RP-HPLC Estimation of Ramipril and Telmisartan in Tablets.

  Indian journal of pharmaceutical sciences 20090101

• [The clinical and hemodynamic efficacy of telmisartan and enalapril in the treatment of arterial hypertension in patients with type 2 diabetes mellitus].

  Terapevticheskii arkhiv 20090101

• [Peripheral vascular remodeling in arterial hypertension in conditions of occupational risk: the issues of pathogenesis and telmisartan therapy].

  Terapevticheskii arkhiv 20090101

• Ion Pair-HPLC Method for the Simultaneous Estimation of Quinapril and Hydrochlorothiazide in Tablets.

  Indian journal of pharmaceutical sciences 20090101

• Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.

  Core evidence 20090101

• Recent advances in management of cerebrovascular diseases.

  F1000 medicine reports 20090101

• Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.

  F1000 medicine reports 20090101

• Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma.

  Molecular medicine reports 20090101

• Can nocturnal hypertension predict cardiovascular risk?

  Integrated blood pressure control 20090101

• Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility.

  Integrated blood pressure control 20090101

• Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors.

  Integrated blood pressure control 20090101

• A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes.

  ACP journal club 20081216

• Synthesis and biological activities of novel nonpeptide angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring.

  Bioorganic & medicinal chemistry 20081215

• Liquid chromatographic-tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma.

  Journal of pharmaceutical and biomedical analysis 20081201

• Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.

  American journal of hypertension 20081201

• Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation.

  Journal of hypertension 20081201

• Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.

  Journal of hypertension 20081201

• Telmisartan and carotid intima-media thickness regression: a class effect of angiotensin-receptor blockers?

  Hypertension research : official journal of the Japanese Society of Hypertension 20081201

• Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.

  Vascular health and risk management 20081201

• Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.

  Vascular health and risk management 20081201

• Long-acting nifedipine in the management of the hypertensive patient.

  Vascular health and risk management 20081201

• Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

  Biologics : targets & therapy 20081201

• Cation exchange induced tunable properties of a nanoporous octanuclear Cu(II) wheel with double-helical structure.

  Journal of the American Chemical Society 20081119

• Concise synthesis of telmisartan via decarboxylative cross-coupling.

  The Journal of organic chemistry 20081107

• Pemphigus foliaceus induced by an angiotensin II receptor blocker.

  Clinical and experimental dermatology 20081101

• Magnitude of the early morning blood pressure surge in untreated hypertensive patients: a pooled analysis.

  International journal of clinical practice 20081101

• Spironolactone attenuates oxidative stress in patients with chronic kidney disease.

  Hypertension (Dallas, Tex. : 1979) 20081101

• American College of Endocrinology Pre-Diabetes Consensus Conference: part two.

  Diabetes care 20081101

• Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?

  Advances in therapy 20081101

• Angiotensin inhibition stimulates PPARgamma and the release of visfatin.

  European journal of clinical investigation 20081101

• In angiotensin-converting enzyme inhibitor-intolerant individuals, the angiotensin receptor blocker telmisartan does not reduce the incidence of major cardiovascular events in high-risk patients: lessons learned from the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects Wtih Cardiovascular Disease (TRANSCEND).

  Journal of clinical hypertension (Greenwich, Conn.) 20081101

• Telmisartan prevented cognitive decline partly due to PPAR-gamma activation.

  Biochemical and biophysical research communications 20081024

• Tritiation of several antihypertensive agents at high specific activity.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20081001

• Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081001

• The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control.

  Diabetes research and clinical practice 20081001

• Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.

  The Lancet. Neurology 20081001

• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  Current hypertension reports 20081001

• ONTARGET Study of Telmisartan, Ramipril, or Both in High-Risk Patients.

  Current hypertension reports 20081001

• Inhibiting angiotensin type 1 receptors as a target for diabetes.

  Expert opinion on therapeutic targets 20081001

• Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.

  Metabolism: clinical and experimental 20081001

• Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.

  International journal of molecular medicine 20081001

• Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor.

  Investigative ophthalmology & visual science 20081001

• Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes.

  Evidence-based medicine 20081001

• Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20081001

• Renoprotective effect of telmisartan in patients with chronic kidney disease.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20081001

• Clinical profile of eprosartan: a different angiotensin II receptor blocker.

  Cardiovascular & hematological agents in medicinal chemistry 20081001

• The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.

  Vascular health and risk management 20081001

• Autonomic nervous system and cardiovascular system.

  Indian journal of pharmacology 20081001

• Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

  Lancet (London, England) 20080927

• The power to TRANSCEND.

  Lancet (London, England) 20080927

• Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

  The New England journal of medicine 20080918

• Telmisartan to prevent recurrent stroke and cardiovascular events.

  The New England journal of medicine 20080918

• Stroke prevention--insights from incoherence.

  The New England journal of medicine 20080918

• [ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].

  MMW Fortschritte der Medizin 20080918

• Aliskiren combined with losartan in diabetes and nephropathy.

  The New England journal of medicine 20080904

• Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20080901

• AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats.

  Free radical biology & medicine 20080901

• Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?

  Nature clinical practice. Cardiovascular medicine 20080901

• [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].

  Der Internist 20080901

• Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.

  Journal of hypertension 20080901

• Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20080901

• [Effects of telmisartan on endoplasmic reticulum stress induced cardiomyocyte apoptosis in abdominal aortic banded rats].

  Zhonghua xin xue guan bing za zhi 20080901

• Evaluation of safety and efficacy of telmisartan-amlodipine combination in treating hypertension.

  Journal of the Indian Medical Association 20080901

• [Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial].

  Nederlands tijdschrift voor geneeskunde 20080830

• [What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?].

  Revue medicale suisse 20080827

• Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium.

  Biochemical and biophysical research communications 20080822

• Renin-angiotensin blockade and kidney disease.

  Lancet (London, England) 20080816

• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

  Lancet (London, England) 20080816

• Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice.

  Atherosclerosis 20080801

• Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina.

  Diabetes 20080801

• Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.

  Kidney international 20080801

• Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080801

• Telmisartan is a potent target for prevention and treatment in human prostate cancer.

  Oncology reports 20080801

• Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes.

  Acta pharmacologica Sinica 20080801

• Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20080801

• ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.

  Therapeutic advances in cardiovascular disease 20080801

• Telmisartan, ramipril, or both in patients at high risk of vascular events.

  The New England journal of medicine 20080724

• Telmisartan, ramipril, or both in patients at high risk of vascular events.

  The New England journal of medicine 20080724

• Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release.

  Journal of controlled release : official journal of the Controlled Release Society 20080702

• Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats.

  Molecular and cellular biochemistry 20080701

• A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.

  Nature clinical practice. Cardiovascular medicine 20080701

• Beyond the classic angiotensin-receptor-blocker profile.

  Nature clinical practice. Cardiovascular medicine 20080701

• The value of current interventions for obesity.

  Nature clinical practice. Cardiovascular medicine 20080701

• Reduction of proteinuria with angiotensin receptor blockers.

  Nature clinical practice. Cardiovascular medicine 20080701

• The effect of enalapril and telmisartan on clinical and biochemical indices of sympathetic activity in hypertensive patients.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20080701

• [A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20080701

• [No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk].

  Nederlands tijdschrift voor geneeskunde 20080614

• Telmisartan as a metabolic sartan for targeting vascular failure.

  Expert opinion on pharmacotherapy 20080601

• Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.

  Journal of hypertension 20080601

• Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.

  Expert review of cardiovascular therapy 20080601

• ONTARGET: questions asked, questions answered.

  Journal of clinical hypertension (Greenwich, Conn.) 20080601

• Effect of Micardis on the expression of renal medulla aquaporin-2 in diabetic mice.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20080601

• Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20080601

• Effect of the angiotensin II receptor antagonist telmisartan on lipoprotein lipase mass in preheparin serum.

  Journal of atherosclerosis and thrombosis 20080601

• [Commentary to the article: ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59].

  Kardiologia polska 20080601

• The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies.

  Blood pressure. Supplement 20080601

• Early vascular aging (EVA): consequences and prevention.

  Vascular health and risk management 20080601

• Methyl 3-amino-4-butanamido-5-methyl-benzoate.

  Acta crystallographica. Section E, Structure reports online 20080601

• [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].

  Praxis 20080514

• Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells.

  Atherosclerosis 20080501

• Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan.

  Diabetes 20080501

• Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension.

  Journal of human hypertension 20080501

• Therapeutic strategies to slow chronic kidney disease progression.

  Pediatric nephrology (Berlin, Germany) 20080501

• Pleiotropic effects of telmisartan: still more to come?

  Journal of hypertension 20080501

• Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.

  Journal of hypertension 20080501

• Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?

  Journal of hypertension 20080501

• Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats.

  Journal of cardiovascular pharmacology 20080501

• Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension.

  American journal of hypertension 20080501

• Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.

  American journal of hypertension 20080501

• Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease.

  Reviews on recent clinical trials 20080501

• [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].

  Lakartidningen 20080501

• Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080501

• Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080501

• Methyl 4-amino-3-methyl-benzoate.

  Acta crystallographica. Section E, Structure reports online 20080501

• [What is better here: ACE inhibitor or AT1 blocker?].

  MMW Fortschritte der Medizin 20080417

• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  The New England journal of medicine 20080410

• ACE inhibitors in cardiovascular disease--unbeatable?

  The New England journal of medicine 20080410

• Protective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure.

  Experimental neurology 20080401

• Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.

  Drug metabolism and disposition: the biological fate of chemicals 20080401

• A physician with pounding headaches.

  Blood pressure monitoring 20080401

• Immediate release tablets of telmisartan using superdisintegrant-formulation, evaluation and stability studies.

  Chemical & pharmaceutical bulletin 20080401

• [An experimental study of expression of angiotension converting enzyme 2 in myocardium and effect of telmisartan treatment in pressure-overloaded rats].

  Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 20080401

• Telmisartan in the treatment of hypertension.

  Expert opinion on drug metabolism & toxicology 20080401

• Early detection and management of the high-risk patient with elevated blood pressure.

  Vascular health and risk management 20080401

• [ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events].

  Revue medicale de Liege 20080401

• Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080401

• Telmisartan, an angiotensin II type 1 receptor blocker, improves coronary microcirculation and insulin resistance among essential hypertensive patients without left ventricular hypertrophy.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080401

• Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080401

• [A randomized, double-blind, double-dummy study comparing a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg to telmisartan 80 mg in Chinese hypertensive patients who failed to respond adequately to telmisartan 80 mg].

  Zhonghua xin xue guan bing za zhi 20080401

• Methyl 4-(butyrylamino)-5-methyl-2-nitro-benzoate.

  Acta crystallographica. Section E, Structure reports online 20080401

• Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers.

  Pharmaceutical research 20080301

• Cardiovascular reactivity after blockade of angiotensin AT1 receptors in the experimental model of tilting test in conscious rats.

  British journal of pharmacology 20080301

• Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.

  Hypertension (Dallas, Tex. : 1979) 20080301

• Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method.

  Journal of separation science 20080301

• Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.

  Expert review of cardiovascular therapy 20080301

• Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080301

• Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.

  Journal of the Indian Medical Association 20080301

• Persistence with antihypertensive medication: Australia-wide experience, 2004-2006.

  The Medical journal of Australia 20080218

• [Metabolic syndrome: jumble syndrome of obesity or specific entity? Which treatment: diet or polypill?].

  Revue medicale suisse 20080206

• Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation.

  Human reproduction (Oxford, England) 20080201

• Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.

  Hypertension (Dallas, Tex. : 1979) 20080201

• Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.

  Blood pressure monitoring 20080201

• Angiotensin II induces oxidative stress in prostate cancer.

  Molecular cancer research : MCR 20080201

• Carvedilol in hypertension treatment.

  Vascular health and risk management 20080201

• The effect of advertising in clinical software on general practitioners' prescribing behaviour.

  The Medical journal of Australia 20080107

• Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report.

  Progress in neuro-psychopharmacology & biological psychiatry 20080101

• Expression of NG,NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers.

  Diabetes 20080101

• Plasma renin activity for predicting antihypertensive drug efficacy.

  American journal of hypertension 20080101

• Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension.

  American journal of hypertension 20080101

• Effect of telmisartan and amlodipine on home blood pressure by monitoring newly developed telemedicine system: monitoring test by using telemedicine. Telmisartan's effect on home blood pressure (TelTelbosu).

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20080101

• PPAR Agonists and Cardiovascular Disease in Diabetes.

  PPAR research 20080101

• Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model.

  Cardiovascular diabetology 20080101

• ONTARGET programme of cardio- and vascular protection - first results are imminent.

  Cardiovascular journal of Africa 20080101

• Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080101

• The MUSCAT study: a Multicenter PROBE Study Comparing the Effects of Angiotensin II Type-1 Receptor Blockers on Self-Monitored Home Blood Pressure in Patients with Morning Hypertension: study design and background characteristics.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080101

• Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080101

• Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080101

• Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation.

  The Journal of international medical research 20080101

• Correction to the PRoFESS Trial paper by Diener et al. (Cerebrovasc Dis 2007;23:368-80.

  Cerebrovascular diseases (Basel, Switzerland) 20080101

• No HOPE without proof: do ARBs meet the standard for cardiovascular protection?

  Medscape journal of medicine 20080101

• Cardiac and vascular protection: the potential of ONTARGET.

  Medscape journal of medicine 20080101

• Targeting cardiovascular protection: the concept of dual renin-angiotensin system control.

  Medscape journal of medicine 20080101

• Prospects for renovascular protection by more aggressive renin-angiotensin system control.

  Medscape journal of medicine 20080101

• Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.

  Current pharmaceutical design 20080101

• PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies.

  PPAR research 20080101

• ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.

  Cardiovascular journal of Africa 20080101

• [Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].

  Kardiologiia 20080101

• Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.

  Drugs 20080101

• Olmesartan medoxomil: a review of its use in the management of hypertension.

  Drugs 20080101

• Early initiation of BP lowering with telmisartan after a stroke. PRoFESS results: addition of telmisartan 80 mg compared to placebo in ischaemic stroke.

  Cardiovascular journal of Africa 20080101

• A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET.

  Blood pressure 20080101

• Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats.

  Pharmacological reports : PR 20080101

• Lessons from ONTARGET.

  Acta clinica Belgica 20080101

• Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension.

  Drugs 20080101

• Effects of angiotensin II receptor blockers on renal handling of uric acid in rats.

  Drug metabolism and pharmacokinetics 20080101

• Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI).

  The Journal of international medical research 20080101

• Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation.

  Protein and peptide letters 20080101

• Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?

  Cerebrovascular diseases (Basel, Switzerland) 20080101

• The prince and the pauper. A tale of anticancer targeted agents.

  Molecular cancer 20080101

• Telmisartan shown to reduce cardiovascular death, myocardial infarction and stroke in ACE-intolerant high-risk patients.

  Cardiovascular journal of Africa 20080101

• Simultaneous high-performance liquid chromatographic determination of telmisartan and hydrochlorothiazide in pharmaceutical preparation.

  Journal of chromatographic science 20080101

• [Double blockade of the renin-angiotensin system (RAS): what has the ONTARGET study taught us?].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20080101

• [Remodelling of peripheral vessels in cardiovascular diseases: pathogenesis and treatment with telmisartan].

  Meditsina truda i promyshlennaia ekologiia 20080101

• [Antihypertensive and organ-protective action of a 36-week monotherapy with telmisartan in hypertensive patients].

  Terapevticheskii arkhiv 20080101

• Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.

  Scandinavian journal of urology and nephrology 20080101

• Peroxisome proliferator-activated receptors in diabetic nephropathy.

  PPAR research 20080101

• PPARgamma in Kidney Physiology and Pathophysiology.

  PPAR research 20080101

• Metabolic syndrome and chronic kidney disease.

  Indian journal of nephrology 20080101

• 24-hour powerful blood pressure-lowering: is there a clinical need?

  Journal of the American Society of Hypertension : JASH 20080101

• Does it matter how blood pressure is lowered in patients with metabolic risk factors?

  Journal of the American Society of Hypertension : JASH 20080101

• Slowing the progression of kidney disease in patients with diabetes.

  Journal of the American Society of Hypertension : JASH 20080101

• Preventing stroke in hypertensive patients at risk.

  Journal of the American Society of Hypertension : JASH 20080101

• Is the combination of enalapril and losartan irrational?

  Indian journal of pharmacology 20080101

• Angiotensin receptor blockers and microalbuminuria in hypertensive patients with early (microalbuminuric) stage diabetic nephropathy.

  Molecular medicine reports 20080101

• Differential response of vascular hepatocyte growth factor concentration and lipid accumulation between telmisartan and losartan in ApoE-deficient mice.

  Molecular medicine reports 20080101

• Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet.

  Biochemical and biophysical research communications 20071228

• WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats.

  European journal of pharmacology 20071222

• [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].

  MMW Fortschritte der Medizin 20071206

• Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study.

  European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 20071201

• Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.

  Digestive diseases and sciences 20071201

• Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide.

  International journal of clinical practice 20071201

• Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats.

  British journal of pharmacology 20071201

• Potential utility of combination therapy with nateglinide and telmisartan for metabolic derangements in Zucker Fatty rats.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20071201

• Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients.

  The American journal of cardiology 20071201

• Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression.

  Therapeutic drug monitoring 20071201

• Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.

  American journal of hypertension 20071201

• Change in forearm reactive hyperemia after telmisartan: an endothelial effect?

  American journal of hypertension 20071201

• Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series.

  Croatian medical journal 20071201

• Peroxynitrite is Involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats.

  Journal of cardiovascular pharmacology 20071201

• Clinical trial update: focus on the ONTARGET study.

  Vascular health and risk management 20071201

• Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature.

  Vascular health and risk management 20071201

• Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.

  Clinical therapeutics 20071201

• Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.

  Hypertension research : official journal of the Japanese Society of Hypertension 20071201

• Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20071201

• Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.

  Kidney international 20071101

• Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients.

  Journal of clinical hypertension (Greenwich, Conn.) 20071101

• Development of a solid phase extraction procedure for HPLC-DAD determination of several angiotensin II receptor antagonists in human urine using mixture design.

  Talanta 20071015

• Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension.

  Hypertension (Dallas, Tex. : 1979) 20071001

• [Nephrotoxicity of high- and low-osmolar contrast media: Protective role of fosinopril or telmisartan in a rat model].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20071001

• Telmisartan improves endothelial function in patients with essential hypertension.

  Journal of cardiovascular pharmacology 20071001

• Pharmacoeconomics and quality of life analysis of telmisartan in hypertension treatment.

  Expert review of pharmacoeconomics & outcomes research 20071001

• Design, statistical analysis and sample size calculation of dose response study of telmisartan and hydrochlorothiazide.

  Contemporary clinical trials 20070901

• Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage.

  The Journal of pharmacology and experimental therapeutics 20070901

• Increasing telmisartan vs amlodipine dose in patients with hypertension, type 2 diabetes and microalbuminuria.

  Nature clinical practice. Nephrology 20070901

• Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus.

  Pharmacological research 20070901

• The effects of simultaneous administration of dietary conjugated linoleic acid and telmisartan on cardiovascular risks in rats.

  Lipids 20070901

• Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.

  Investigative ophthalmology & visual science 20070901

• The PRoFESS trial: future impact on secondary stroke prevention.

  Expert review of neurotherapeutics 20070901

• Cardiovascular disease in patients with chronic kidney disease. A clinical review.

  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20070901

• The relationship between the acute changes of the systolic blood pressure and the brachial-ankle pulse wave velocity.

  The Korean journal of internal medicine 20070901

• Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1).

  International heart journal 20070901

• [Observational study of an AT1-antagonist].

  MMW Fortschritte der Medizin 20070816

• Prevention of stroke in patients with hypertension.

  The American journal of cardiology 20070806

• Rationale for double renin-angiotensin-aldosterone system blockade.

  The American journal of cardiology 20070806

• Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?

  The American journal of cardiology 20070806

• New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

  The American journal of cardiology 20070806

• Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.

  Diabetes research and clinical practice 20070801

• Enhancement effect of sodium dodecyl benzene sulfonate (SDBS) and its application into voltammetric determination of telmisartan.

  Colloids and surfaces. B, Biointerfaces 20070801

• Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients.

  Journal of human hypertension 20070801

• Do all angiotensin II type 1 receptor blockers have the same beneficial effects?

  British journal of pharmacology 20070801

• Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

  British journal of pharmacology 20070801

• Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker.

  Journal of hypertension 20070801

• Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients.

  Cardiovascular drugs and therapy 20070801

• ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.

  Cardiovascular drugs and therapy 20070801

• Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.

  Current molecular medicine 20070801

• Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20070801

• Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.

  Acta cardiologica 20070801

• Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes.

  Drug metabolism and pharmacokinetics 20070801

• Arterial stiffness and pharmacological interventions--the TRanscend arterial stiffNess Substudy (TRANS study).

  Vascular health and risk management 20070801

• [Protein kinase C-betaI, betaII in mouse diabetic nephropathy kidney and its relation to nephroprotective actions of the angiotensin receptor blocker telmisartan].

  Zhonghua yi xue za zhi 20070724

• Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties.

  American journal of physiology. Endocrinology and metabolism 20070701

• Telmisartan shows an equivalent effect of vitamin C in further improving endothelial dysfunction after glycemia normalization in type 1 diabetes.

  Diabetes care 20070701

• Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).

  American heart journal 20070701

• Effect of telmisartan in experimentally induced diabetetes mellitus in rats.

  International journal of health sciences 20070701

• [Treatment of hypertension in daily practice. Current results of a postmarketing surveillance study with telmisartan].

  MMW Fortschritte der Medizin 20070628

• Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action.

  The Prostate 20070615

• AT1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NOS inhibition in humans.

  Clinical science (London, England : 1979) 20070601

• Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.

  Diabetes care 20070601

• Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes.

  Diabetes care 20070601

• Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

  Journal of clinical pharmacy and therapeutics 20070601

• The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.

  Blood pressure monitoring 20070601

• Effect of telmisartan on expression of protein kinase C-alpha in kidneys of diabetic mice.

  Acta pharmacologica Sinica 20070601

• Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma.

  Journal of atherosclerosis and thrombosis 20070601

• Beneficial effect of beraprost sodium plus telmisartan in the prevention of arterial stiffness development in elderly patients with hypertension and cerebral infarction.

  Prostaglandins, leukotrienes, and essential fatty acids 20070601

• Effects of the angiotensin II type 1 receptor antagonist telmisartan on monocyte adhesion and activation in patients with essential hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070601

• Renoprotective effects of telmisartan in the 5/6 nephrectomised rats.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20070601

• Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?

  Vascular health and risk management 20070601

• [ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].

  Nihon rinsho. Japanese journal of clinical medicine 20070528

• Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma activation.

  Biochemical and biophysical research communications 20070518

• Simultaneous determination of 6 beta-blockers, 3 calcium-channel antagonists, 4 angiotensin-II antagonists and 1 antiarrhythmic drug in post-mortem whole blood by automated solid phase extraction and liquid chromatography mass spectrometry. Method development and robustness testing by experimental design.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Palatability of angiotensin II antagonists among nephropathic children.

  British journal of clinical pharmacology 20070501

• Pharmacokinetic-pharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats.

  Acta pharmacologica Sinica 20070501

• The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.

  American journal of hypertension 20070501

• Effect of telmisartan on cholesterol levels in patients with hypertension - Saga Telmisartan Aggressive Research (STAR).

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20070501

• Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

  Current opinion in pharmacology 20070401

• Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.

  Journal of hypertension 20070401

• Angiotensin II receptor blockers for the treatment of heart failure: a class effect?

  Pharmacotherapy 20070401

• Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.

  American journal of hypertension 20070401

• Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.

  American journal of hypertension 20070401

• Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension.

  Stem cells and development 20070401

• [New therapeutic targets for ACE inhibitors and angiotensin receptor blockers].

  Polskie Archiwum Medycyny Wewnetrznej 20070401

• Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.

  Circulation 20070320

• Determination of clarithromycin in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20070312

• Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension.

  Journal of clinical pharmacology 20070301

• C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice.

  Circulation 20070227

• Telmisartan attenuates chronic ciclosporin A nephrotoxicity in a pig model.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070201

• Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.

  Diabetologia 20070201

• The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?

  Expert opinion on therapeutic targets 20070201

• Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.

  Vascular health and risk management 20070201

• Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials.

  Vascular health and risk management 20070201

• Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.

  The Journal of pharmacology and experimental therapeutics 20070101

• Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).

  Cerebrovascular diseases (Basel, Switzerland) 20070101

• Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects.

  PPAR research 20070101

• Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.

  Cardiovascular diabetology 20070101

• Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070101

• Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes.

  Advances in therapy 20070101

• [Antihypertensive and metabolic effects of telmisartan in patients with the metabolic syndrome in primary care--a field study].

  Wiener medizinische Wochenschrift (1946) 20070101

• ONTARGET to provide new treatment strategies for high-risk cardiovascular patients. Understanding the role of PPARgamma in blood pressure control.

  Cardiovascular journal of Africa 20070101

• Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.

  The Journal of international medical research 20070101

• Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.

  Internal medicine (Tokyo, Japan) 20070101

• Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20070101

• Telmisartan-enhanced hypercholesterolaemic serum-induced vascular endothelial growth factor expression in immortalized human umbilical vascular endothelial cells.

  Scandinavian journal of clinical and laboratory investigation 20070101

• Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records.

  Cardiovascular diabetology 20070101

• Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.

  Cardiovascular diabetology 20070101

• Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure.

  Clinical drug investigation 20070101

• Clinical assessment of early morning blood pressure in patients with hypertension.

  Preventive cardiology 20070101

• A perspective on telmisartan and cardiovascular risk.

  Reviews in cardiovascular medicine 20070101

• Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study.

  Cardiovascular diabetology 20070101

• Effects of eprosartan on serum metabolic parameters in patients with essential hypertension.

  The open cardiovascular medicine journal 20070101

• Telmisartan ramipril combination therapy reduces strokes and improves cardiac and renal protection in stroke prone spontaneously hypertensive rats.

  Journal of the American Society of Hypertension : JASH 20070101

• Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension.

  Journal of molecular and cellular cardiology 20061201

• Rapid identification of P-glycoprotein substrates and inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20061201

• Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation.

  Diabetologia 20061201

• Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.

  Proteins 20061201

• Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation.

  Investigative ophthalmology & visual science 20061201

• The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.

  Journal of endocrinological investigation 20061201

• Potential protective effects of telmisartan on renal function deterioration.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20061201

• The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20061201

• Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.

  Vascular health and risk management 20061201

• Intracellular angiotensin II induces cell proliferation independent of AT1 receptor.

  American journal of physiology. Cell physiology 20061101

• Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system.

  Journal of molecular and cellular cardiology 20061101

• Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

  Journal of the American Society of Nephrology : JASN 20061101

• Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.

  Hypertension research : official journal of the Japanese Society of Hypertension 20061101

• Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization.

  Arteriosclerosis, thrombosis, and vascular biology 20061001

• Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.

  Cardiovascular research 20061001

• Drug interactions and drugs that affect blood pressure.

  Journal of clinical hypertension (Greenwich, Conn.) 20061001

• Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.

  Vascular pharmacology 20060901

• Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.

  Journal of hypertension 20060901

• Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes.

  Journal of hypertension 20060901

• The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.

  Metabolism: clinical and experimental 20060901

• Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.

  Metabolism: clinical and experimental 20060901

• Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20060901

• Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.

  Expert review of cardiovascular therapy 20060901

• A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours.

  Vascular health and risk management 20060901

• Effects of nine antihypertensive drugs on blood pressure variability in sinoaortic-denervated rats.

  Acta pharmacologica Sinica 20060801

• Renal and vascular protective effects of telmisartan in patients with essential hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20060801

• [Lowering blood pressure substantially--and the diabetes risk as well?].

  MMW Fortschritte der Medizin 20060720

• Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20060701

• Metabolic effects of telmisartan in spontaneously hypertensive rats.

  Naunyn-Schmiedeberg's archives of pharmacology 20060701

• Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice.

  Hypertension (Dallas, Tex. : 1979) 20060701

• [PPARgamma-activating properties of angiotensin receptor blockers].

  Nihon rinsho. Japanese journal of clinical medicine 20060701

• [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].

  MMW Fortschritte der Medizin 20060629

• [In the DETAIL. Kidney protection in manifestations of microalbuminuria].

  MMW Fortschritte der Medizin 20060629

• Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

  Atherosclerosis 20060601

• [Role of angiotensin II receptor antagonists in the treatment of metabolic syndrome].

  Revista clinica espanola 20060601

• Pharmacokinetic simulations and AUC: center specificity in the limited sampling model.

  International journal of clinical pharmacology and therapeutics 20060601

• Ventricular hypertrophy and hypertension: prognostic elements and implications for management.

  Herz 20060601

• The obese patient with diabetes mellitus: from research targets to treatment options.

  The American journal of medicine 20060501

• New treatment strategies for patients with hypertension and insulin resistance.

  The American journal of medicine 20060501

• Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns.

  The American journal of medicine 20060501

• Prevention of loss of renal function over time in patients with diabetic nephropathy.

  The American journal of medicine 20060501

• Telmisartan: the ACE of ARBs?

  Hypertension (Dallas, Tex. : 1979) 20060501

• Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis.

  Hypertension (Dallas, Tex. : 1979) 20060501

• New and emerging strategies for reducing cardiometabolic risk factors.

  Pharmacotherapy 20060501

• [Clinical study on treatment of early diabetic nephropathy by tangshenling combined with telmisartan].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20060501

• Selective increase of dark phase water intake in neuropeptide-Y Y2 and Y4 receptor knockout mice.

  Behavioural brain research 20060403

• Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.

  Journal of the American Society of Nephrology : JASN 20060401

• An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements.

  Journal of clinical hypertension (Greenwich, Conn.) 20060401

• Circadian rhythm of blood pressure and the relation to cardiovascular events.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20060401

• Prospects for the prevention of stroke.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20060401

• Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20060401

• Hypertension treatment and implications of recent cardiovascular outcome trials.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20060401

• [Study on up-regulation of the expression of angiotensin-converting enzyme-2 in human umbilical vein endothelial cells by telmisartan].

  Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 20060401

• Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients.

  Journal of human hypertension 20060301

• Targeting effective blood pressure control with angiotensin receptor blockers.

  International journal of clinical practice 20060301

• Determination of telmisartan in rat tissues by in-tube solid-phase microextraction coupled to high performance liquid chromatography.

  Journal of separation science 20060301

• Effects of eprosartan on target organ protection.

  Vascular health and risk management 20060301

• Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.

  Diabetes research and clinical practice 20060201

• Novel polymer monolith microextraction using a poly(methacrylic acid-ethylene glycol dimethacrylate) monolith and its application to simultaneous analysis of several angiotensin II receptor antagonists in human urine by capillary zone electrophoresis.

  Journal of chromatography. A 20060113

• Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.

  Medical hypotheses 20060101

• Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.

  The international journal of biochemistry & cell biology 20060101

• The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).

  Journal of hypertension 20060101

• Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting.

  American heart journal 20060101

• Telmisartan: a review of its use in the management of hypertension.

  Drugs 20060101

• Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.

  Theoretical biology & medical modelling 20060101

• A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.

  American journal of hypertension 20060101

• Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial.

  Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20060101

• Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study.

  The American journal of geriatric cardiology 20060101

• Genetic variants of adiponectin receptor 2 are associated with increased adiponectin levels and decreased triglyceride/VLDL levels in patients with metabolic syndrome.

  Cardiovascular diabetology 20060101

• C-reactive protein (CRP)-lowering agents.

  Cardiovascular drug reviews 20060101

• Telmisartan provides superior BP reduction from morning to morning compared to other leading ARBs.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20060101

• Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels.

  Arzneimittel-Forschung 20060101

• High prevalence of ACE DD genotype among north Indian end stage renal disease patients.

  BMC nephrology 20060101

• [The role of telmisartan in the treatment of metabolic syndrome].

  Terapevticheskii arkhiv 20060101

• Ligand-based approach to in silico pharmacology: nuclear receptor profiling.

  Journal of chemical information and modeling 20060101

• A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.

  PloS one 20060101

• [Control of blood pressure morning surge in a Lebanese hypertensive population].

  Le Journal medical libanais. The Lebanese medical journal 20060101

• Telmisartan, its potential therapeutic implications in cardiometabolic disorders.

  Recent patents on cardiovascular drug discovery 20060101

• Determination of telmisartan in human plasma by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051215

• Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051215

• [Revised blood pressure goals and no elevated glucose readings in between].

  MMW Fortschritte der Medizin 20051215

• Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.

  Journal of human hypertension 20051201

• Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20051201

• Constrictor and dilator effects of angiotensin II on cerebral arterioles.

  Stroke 20051201

• Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.

  Diabetes 20051201

• Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20051201

• Transepithelial transport of telmisartan in caco-2 monolayers.

  Biological & pharmaceutical bulletin 20051201

• Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.

  American journal of hypertension 20051201

• Angiotensin II type 1 receptor antagonist protects ventricular and coronary endothelial function after 24-hour heart preservation.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20051201

• Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients.

  Hypertension research : official journal of the Japanese Society of Hypertension 20051201

• A hypertensive snow bird.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20051122

• A hypertensive snow bird.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20051122

• Patterns of antihypertensive therapy in new users of angiotensin II-receptor blockers.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20051115

• The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.

  Journal of hypertension 20051101

• Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.

  Microvascular research 20051101

• Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.

  Clinical therapeutics 20051101

• Application of first-derivative, ratio derivative spectrophotometry, TLC-densitometry and spectrofluorimetry for the simultaneous determination of telmisartan and hydrochlorothiazide in pharmaceutical dosage forms and plasma.

  Farmaco (Societa chimica italiana : 1989) 20051001

• Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.

  Journal of clinical hypertension (Greenwich, Conn.) 20051001

• Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.

  Atherosclerosis 20050901

• The prevention of type 2 diabetes: what is the evidence?

  Minerva endocrinologica 20050901

• [Telmisartan in monotherapy of essential hypertension in young men--time of drug administration and 24-hours blood pressure and heart rate].

  Polskie Archiwum Medycyny Wewnetrznej 20050901

• Lercanidipine in hypertension.

  Vascular health and risk management 20050901

• Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression.

  FEBS letters 20050815

• Suppression of ocular inflammation in endotoxin-induced uveitis by blocking the angiotensin II type 1 receptor.

  Investigative ophthalmology & visual science 20050801

• Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.

  Current hypertension reports 20050801

• Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease.

  Blood pressure monitoring 20050801

• Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20050801

• Modulation of the (Na(+)+K+)ATPase activity by Angiotensin-(1-7) in MDCK cells.

  Regulatory peptides 20050715

• PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.

  Hypertension (Dallas, Tex. : 1979) 20050701

• Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20050701

• Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling.

  Hypertension research : official journal of the Japanese Society of Hypertension 20050701

• ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.

  Vascular medicine (London, England) 20050701

• Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.

  Journal of medicinal chemistry 20050630

• Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.

  Journal of hypertension 20050601

• Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus.

  The American journal of cardiology 20050601

• Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial.

  Blood pressure monitoring 20050601

• Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice.

  Arthritis and rheumatism 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• HPLC determination of telmisartan in human plasma and its application to a pharmacokinetic study.

  Die Pharmazie 20050601

• The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study.

  Clinical cardiology 20050601

• Have angiotensin receptor blockers lived up to expectations?

  The Canadian journal of cardiology 20050515

• Coronary arteriolar vasoconstriction to angiotensin II is augmented in prediabetic metabolic syndrome via activation of AT1 receptors.

  American journal of physiology. Heart and circulatory physiology 20050501

• Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats.

  Journal of hypertension 20050501

• Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation.

  American journal of hypertension 20050501

• Telmisartan/hydrochlorothiazide: a new fixed dose combination.

  Expert review of cardiovascular therapy 20050501

• The metabolic effects of angiotensin-receptor blockers.

  Current hypertension reports 20050401

• Blood pressure variability: its measurement and significance in hypertension.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20050401

• Lowering blood pressure for cardiovascular risk reduction.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20050401

• Relevance of blood pressure variation in the circadian onset of cardiovascular events.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20050401

• Managing the patient at risk for a second stroke.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20050401

• The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20050401

• Telmisartan in patients with mild/moderate hypertension and chronic kidney disease.

  Clinical nephrology 20050401

• Introduction.

  Acta diabetologica 20050401

• Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.

  Acta diabetologica 20050401

• Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.

  Acta diabetologica 20050401

• The ONTARGET/TRANSCEND Trial Programme: baseline data.

  Acta diabetologica 20050401

• Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.

  Acta diabetologica 20050401

• Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan.

  Journal of human hypertension 20050301

• Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor.

  Investigative ophthalmology & visual science 20050301

• Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.

  Diabetes care 20050301

• Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?

  Current opinion in investigational drugs (London, England : 2000) 20050301

• [Therapeutic interchange standardization for antiotensin II receptor antagonists in the treatment of hypertension in the hospital setting].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20050301

• A pilot study for evaluation of the efficacy and safety of telmisartan in reducing microalbuminuria in hypertensive patients with type 2 diabetes mellitus.

  Journal of the Indian Medical Association 20050301

• Telmisartan vs. enalapril in type 2 diabetes.

  The New England journal of medicine 20050224

• Telmisartan vs. enalapril in type 2 diabetes.

  The New England journal of medicine 20050224

• Telmisartan vs. enalapril in type 2 diabetes.

  The New England journal of medicine 20050224

• Angiotensin II receptor antagonist treatment during pregnancy.

  Birth defects research. Part A, Clinical and molecular teratology 20050201

• Possible beneficial effect of telmisartan on glycemic control in diabetic subjects.

  Diabetes care 20050201

• Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan.

  American journal of hypertension 20050201

• [PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases].

  Revue medicale de Liege 20050201

• Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients.

  The pharmacogenomics journal 20050101

• Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.

  Medical hypotheses 20050101

• Intraindividual blood pressure responses to angiotensin-converting enzyme inhibition and angiotensin receptor blockade.

  Journal of clinical hypertension (Greenwich, Conn.) 20050101

• Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.

  American journal of hypertension 20050101

• [Assessment of antihypertensive effect of telmizartan in patients with hypertensive disease].

  Kardiologiia 20050101

• Chronobiologically explored effects of Telmisartan.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20050101

• Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.

  International journal of clinical pharmacology research 20050101

• Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.

  Cardiovascular diabetology 20050101

• Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• [New perspectives of preventive pharmacotherapy in metabolic syndrome].

  Terapevticheskii arkhiv 20050101

• [Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials].

  Revue medicale de Liege 20050101

• [Renin-angiotensin system in diabetic nephropathy].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20050101

• [Efficacy of telmisartan in chronic obstructive lung disease wtih arterial hypertension].

  Klinicheskaia meditsina 20050101

• [Telmisartan].

  Krankenpflege Journal 20050101

• Pre-clinical and clinical experience of telmisartan in cardiac remodelling.

  The Journal of international medical research 20050101

• Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension.

  The Journal of international medical research 20050101

• Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene.

  The Journal of international medical research 20050101

• Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.

  The Journal of international medical research 20050101

• Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.

  The Journal of international medical research 20050101

• Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers.

  Advances in therapy 20050101

• Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension.

  Blood pressure 20050101

• The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.

  The Journal of international medical research 20050101

• Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy.

  International journal of tissue reactions 20050101

• Telmisartan: from lowering blood pressure to end-organ protection.

  Future cardiology 20050101

• Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan.

  International journal of cardiology 20041201

• Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.

  Journal of hypertension 20041201

• Introduction. Telmisartan in the treatment of hypertension--addressing the early morning risk: international experiences in different populations.

  International journal of clinical practice. Supplement 20041201

• The normal circadian pattern of blood pressure: implications for treatment.

  International journal of clinical practice. Supplement 20041201

• Effect of telmisartan 80 mg once daily on 24-h blood pressure profile in patients with mild-to-moderate hypertension failing to respond to prior antihypertensive therapy.

  International journal of clinical practice. Supplement 20041201

• A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients.

  International journal of clinical practice. Supplement 20041201

• Clinical efficacy and safety of telmisartan 80 mg once daily compared with enalapril 20 mg once daily in patients with mild-to-moderate hypertension: results of a multicentre study.

  International journal of clinical practice. Supplement 20041201

• Comparison of the efficacy and tolerability of telmisartan 40 mg vs. enalapril 10 mg in the treatment of mild-to-moderate hypertension: a multicentre, double-blind study in Taiwanese patients.

  International journal of clinical practice. Supplement 20041201

• Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension.

  International journal of clinical practice. Supplement 20041201

• A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients.

  International journal of clinical practice. Supplement 20041201

• Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study.

  International journal of clinical practice. Supplement 20041201

• The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension.

  International journal of clinical practice. Supplement 20041201

• Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

  The New England journal of medicine 20041104

• Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension.

  Expert opinion on pharmacotherapy 20041101

• Telmisartan - killing two birds with one stone.

  Expert opinion on pharmacotherapy 20041101

• Control of vascular changes by renin-angiotensin-aldosterone system in salt-sensitive hypertension.

  European journal of pharmacology 20041025

• An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.

  FEBS letters 20041022

• [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].

  MMW Fortschritte der Medizin 20041014

• The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.

  The Annals of pharmacotherapy 20041001

• Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.

  Journal of hypertension 20041001

• Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies.

  Journal of clinical hypertension (Greenwich, Conn.) 20041001

• A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension.

  Blood pressure monitoring 20041001

• [Contribution to the discussion about antihypertensive drugs].

  Orvosi hetilap 20040905

• Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension.

  American journal of hypertension 20040901

• Assessment of efficacy, safety and tolerability of fixed dose combination of telmisartan 40mg and hydrochlorothiazide 12.5mg in adult Indian patients with mild to moderate hypertension.

  Journal of the Indian Medical Association 20040901

• [Despite drug treatment, ever second hypertensive patient with morning blood pressure too high].

  MMW Fortschritte der Medizin 20040819

• Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells.

  Blood 20040815

• Sustained antihypertensive activity of telmisartan compared with valsartan.

  Blood pressure monitoring 20040801

• Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study.

  Clinical therapeutics 20040801

• Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20040801

• Effect of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats.

  Histology and histopathology 20040701

• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.

  American heart journal 20040701

• [Pharmacological and clinical profile of telmisartan, a selective angiotensin II type-1 receptor blocker].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20040701

• Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.

  Hypertension research : official journal of the Japanese Society of Hypertension 20040701

• Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20040701

• Acute pancreatitis induced by telmisartan overdose.

  The Annals of pharmacotherapy 20040601

• [Therapy of hypertension. Pulse pressure must also be reduced].

  MMW Fortschritte der Medizin 20040520

• Regulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload, and neurohumoral activation.

  Circulation 20040511

• [Normal blood pressure values in general practice are not enough. Also measure 'morning after' values].

  MMW Fortschritte der Medizin 20040506

• Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.

  Circulation 20040504

• Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

  Hypertension (Dallas, Tex. : 1979) 20040501

• Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo.

  Journal of hypertension 20040501

• Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.

  Expert opinion on pharmacotherapy 20040501

• Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease.

  Diabetes care 20040401

• Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.

  American journal of hypertension 20040401

• Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.

  Journal of hypertension 20040401

• [Development of combined drugs (ARB and diuretics)].

  Nihon rinsho. Japanese journal of clinical medicine 20040301

• Rapid determination of telmisartan in pharmaceutical preparations and serum by linear sweep polarography.

  Journal of pharmaceutical and biomedical analysis 20040218

• Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method.

  Drug metabolism and pharmacokinetics 20040201

• Relationship between pharmacokinetic parameters and occurrence of adverse events in clinical trials performed in Europe and United States for an angiotensin II receptor antagonist, telmisartan.

  Drug metabolism and pharmacokinetics 20040201

• Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study.

  Journal of human hypertension 20040101

• [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].

  Nihon rinsho. Japanese journal of clinical medicine 20040101

• Safety of telmisartan in patients with arterial hypertension : an open-label observational study.

  Drug safety 20040101

• Increase in systemic blood pressure during intra-arterial PD123319 infusion: evidence for functional expression of angiotensin type 2 receptors in normal volunteers.

  Blood pressure 20040101

• Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.

  Drugs 20040101

• [Effect of telmisartan on the psychological state and quality of life in stable hypertension patients].

  Eksperimental'naia i klinicheskaia farmakologiia 20040101

• [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].

  MMW Fortschritte der Medizin 20031218

• Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the 'dipping' proportion.

  The American journal of cardiology 20031215

• [New possibilities in clinical use of angiotensin II receptor inhibitors].

  Orvosi hetilap 20031207

• Rapid determination of telmisartan in pharmaceuticals and serum by the parallel catalytic hydrogen wave method.

  Analytical and bioanalytical chemistry 20031201

• Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20031201

• Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20031201

• The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy.

  International journal of clinical practice 20031201

• [Therapy of hypertension. Lasting organ protection moves into the foreground].

  MMW Fortschritte der Medizin 20031120

• Center specificity in the limited sampling model (LSM): can the LSM developed from healthy subjects be extended to disease states?

  International journal of clinical pharmacology and therapeutics 20031101

• [Dosage equivalents of AT1-receptor antagonists available in Germany].

  Deutsche medizinische Wochenschrift (1946) 20031031

• [Ask the patient with hypertension about dizziness and headache! High blood pressure in the morning is not a silent killer].

  MMW Fortschritte der Medizin 20031016

• Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril.

  Journal of cardiovascular pharmacology 20031001

• [Therapy of hypertension. Also pulse pressure must be reduced].

  MMW Fortschritte der Medizin 20030911

• [Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].

  Orvosi hetilap 20030907

• [Kinzalkomb, a fixed telmisartan-hydrochlorothiazide combination for the treatment of hypertension].

  Revue medicale de Liege 20030901

• Experimental design approach for the optimisation of a HPLC-fluorimetric method for the quantitation of the angiotensin II receptor antagonist telmisartan in urine.

  Journal of pharmaceutical and biomedical analysis 20030808

• Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study.

  Journal of human hypertension 20030801

• [Recurrence prophylaxis for stroke patients. Which platelet inhibitor combination protects best?].

  MMW Fortschritte der Medizin 20030724

• [When morning blood pressure increases steeply. Stroke risk also increases].

  MMW Fortschritte der Medizin 20030724

• Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements.

  Journal of hypertension 20030701

• Blood pressure lowering and renin-angiotensin system blockade.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20030701

• Relevance of blood pressure variation in the circadian onset of cardiovascular events.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20030701

• The telmisartan programme of research tO show Telmisartan End-organ proteCTION (PROTECTION) programme.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20030701

• Cardiology patient page. Angiotensin receptor blockers.

  Circulation 20030624

• Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.

  Journal of medicinal chemistry 20030605

• [Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].

  MMW Fortschritte der Medizin 20030605

• Different effect of antihypertensive drugs on conduit artery endothelial function.

  Hypertension (Dallas, Tex. : 1979) 20030601

• Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial.

  American journal of hypertension 20030601

• Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies.

  Blood pressure monitoring 20030601

• [PRoFESS study presented. Change in secondary prevention].

  MMW Fortschritte der Medizin 20030526

• How cost-effective are new preventive strategies for cardiovascular disease?

  The American journal of cardiology 20030522

• The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.

  The American journal of cardiology 20030522

• [Morning or evening, in the physicians office or at home. Measured blood pressure values have their peculiarities].

  MMW Fortschritte der Medizin 20030515

• [Diurnal blood pressure control in the optimal treatment of hypertension].

  Orvosi hetilap 20030504

• [Effects of angiotensin receptor inhibitors on cardiovascular endpoints--current and future evidence].

  Orvosi hetilap 20030504

• Angioedema induced by angiotensin II blocker telmisartan.

  Allergy 20030501

• Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension.

  International journal of clinical practice 20030501

• [Therapy of hypertension. Pulse pressure must also be reduced].

  MMW Fortschritte der Medizin 20030501

• Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study.

  Journal of the Indian Medical Association 20030501

• Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis.

  Journal of pharmaceutical and biomedical analysis 20030226

• Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?

  Stroke 20030201

• [Despite therapy morning dangerous RR spikes. Headache and vertigo are alarm signals].

  MMW Fortschritte der Medizin 20030123

• Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of several angiotensin-II-receptor antagonists.

  Journal of chromatography. A 20030110

• Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

  Hypertension (Dallas, Tex. : 1979) 20030101

• Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database.

  Journal of clinical hypertension (Greenwich, Conn.) 20030101

• Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist.

  Journal of perinatology : official journal of the California Perinatal Association 20030101

• Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20030101

• Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial.

  Cardiology 20030101

• Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.

  Drug safety 20030101

• [Telmisartan (micardis) -- an antagonist of angiotensin 2 of type 1 receptors: another antihypertensive drug or something greater?].

  Terapevticheskii arkhiv 20030101

• Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation.

  Drugs under experimental and clinical research 20030101

• Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension.

  Drugs 20030101

• Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation.

  International journal of tissue reactions 20030101

• Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker.

  Journal of clinical hypertension (Greenwich, Conn.) 20030101

• An open-label study investigating the efficacy and safety of 12-96 weeks of telmisartan treatment in patients with hypertension.

  The Journal of international medical research 20030101

• The acute effect of ACEI and ARB's upon endothelin in heart failure patients.

  Romanian journal of internal medicine = Revue roumaine de medecine interne 20030101

• Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients.

  Drug metabolism and pharmacokinetics 20030101

• Telmisartan in hemodialysis.

  Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20030101

• Optimization and validation of a capillary zone electrophoretic method for the analysis of several angiotensin-II-receptor antagonists.

  Journal of chromatography. A 20021206

• Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study.

  Journal of human hypertension 20021201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021201

• [Lowering blood pressure with sartans. Are there differences?].

  MMW Fortschritte der Medizin 20021121

• [These hypertensive patients are especially at risk for myocardial infarct in the morning. Screen for non-dippers].

  MMW Fortschritte der Medizin 20021114

• Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications.

  The Annals of pharmacotherapy 20021101

• Angiotensin blockade prevents type 2 diabetes by formation of fat cells.

  Hypertension (Dallas, Tex. : 1979) 20021101

• [Tendency and prospect of the development of new ARBs].

  Nihon rinsho. Japanese journal of clinical medicine 20021001

• A multicenter, open-label study of the efficacy and safety of telmisartan in mild to moderate hypertensive patients.

  Arquivos brasileiros de cardiologia 20021001

• Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril.

  Clinical therapeutics 20021001

• In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.

  The Journal of pharmacology and experimental therapeutics 20020901

• Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.

  Journal of hypertension 20020901

• The efficacy and tolerability of an angiotensin II receptor blocker, telmisartan, in Thai patients with mild to moderate essential hypertension.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20020901

• Stimulation of collagen gel contraction by angiotensin II and III in cardiac fibroblasts.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20020901

• Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20020901

• Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.

  Hypertension (Dallas, Tex. : 1979) 20020801

• Sympatho-inhibitory properties of various AT1 receptor antagonists.

  Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020601

• [Irbesartan: a new possibility in the treatment of hypertension].

  Orvosi hetilap 20020526

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20020501

• Angiotensin II receptor antagonists role in arterial hypertension.

  Journal of human hypertension 20020301

• [Regardless of therapy only every fifth person has normal blood pressure values. Morning hours are deadly].

  MMW Fortschritte der Medizin 20020214

• Renal hemodynamic control by endothelin and nitric oxide under angiotensin II blockade in man.

  Hypertension (Dallas, Tex. : 1979) 20020201

• Angiotensin II and trials of cardiovascular outcomes.

  The American journal of cardiology 20020124

• From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.

  The American journal of cardiology 20020124

• The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?

  The American journal of cardiology 20020124

• [Coronary heart disease patient with hypertension. Dangerously increased blood pressure despite gigantic therapy arsenal].

  MMW Fortschritte der Medizin 20020124

• Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.

  Electrophoresis 20020101

• Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?

  Drug safety 20020101

• Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension.

  American journal of therapeutics 20020101

• Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.

  Journal of diabetes and its complications 20020101

• Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety.

  Blood pressure 20020101

• A chronotherapeutic approach to effective blood pressure management.

  Journal of clinical hypertension (Greenwich, Conn.) 20020101

• Comparative effects of telmisartan in the treatment of hypertension.

  Journal of clinical hypertension (Greenwich, Conn.) 20020101

• Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.

  Journal of clinical hypertension (Greenwich, Conn.) 20020101

• A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide.

  The Journal of international medical research 20020101

• [Evaluation of blood pressure self-monitoring of the residual efficacy of telmisartan compared to perindopril. The EVERESTE study].

  Archives des maladies du coeur et des vaisseaux 20020101

• Telmisartan. BIBR 277, Micardis, Pritor.

  Drugs in R&D 20020101

• Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications.

  Blood pressure 20020101

• [Hypotensive effects of telmisartan on blood pressure during rest and exercise in patients with mild and moderate arterial hypertension].

  Medicina (Kaunas, Lithuania) 20020101

• [Angiotensin II receptor blocker telmisartan: effect on 24-hour blood pressure profile and left ventricular hypertrophy in patients with hypertension].

  Kardiologiia 20020101

• ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension.

  The Journal of international medical research 20020101

• Search of antimicrobial activity of selected non-antibiotic drugs.

  Acta poloniae pharmaceutica 20020101

• Effects of AT1 receptor antagonist therapy in patients with severe heart failure pretreated with angiotensin-converting enzyme inhibitors.

  Experimental and clinical cardiology 20020101

• Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20011201

• Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge.

  Journal of cardiovascular pharmacology 20011101

• Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy.

  Journal of human hypertension 20011101

• [Preventing cardiovascular diseases. Discovering the optimal approach].

  MMW Fortschritte der Medizin 20011011

• pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.

  Journal of pharmaceutical and biomedical analysis 20011001

• Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and Type 2 diabetes mellitus.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20010901

• AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats.

  The Journal of pharmacology and experimental therapeutics 20010701

• Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.

  Journal of cardiovascular pharmacology 20010701

• Effect of telmisartan on angiotensin II-mediated collagen gel contraction by adult rat cardiac fibroblasts.

  Journal of cardiovascular pharmacology 20010701

• Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs.

  Managed care interface 20010701

• Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.

  Clinical therapeutics 20010601

• Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20010601

• Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20010601

• Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.

  Postgraduate medicine 20010401

• Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?

  Cleveland Clinic journal of medicine 20010301

• Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.

  Journal of hypertension 20010301

• Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20010301

• [Angiotensin II antagonism. Critical morning hours are covered].

  MMW Fortschritte der Medizin 20010222

• Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators.

  International journal of cardiology 20010201

• Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension.

  Clinical cardiology 20010101

• Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study.

  Clinical therapeutics 20010101

• Renal effects of angiotensin II receptor antagonists.

  Blood pressure. Supplement 20010101

• The role of angiotensin II receptor antagonists in the management of diabetes.

  Blood pressure. Supplement 20010101

• Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker--telmisartan.

  Blood pressure. Supplement 20010101

• Angiotensin II receptor antagonists: new paradigms in the treatment of hypertension. Introduction.

  Blood pressure. Supplement 20010101

• The comparative pharmacology of angiotensin II receptor antagonists.

  Blood pressure. Supplement 20010101

• Effects of telmisartan on renal excretory function in conscious dogs.

  The Journal of international medical research 20010101

• [Angiotensin receptor blockers--significance for the therapy of hypertension].

  Wiener medizinische Wochenschrift (1946) 20010101

• Study at up to 700 sites will build on landmark HOPE trial.

  Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20010101

• Micardis/HCT (telmisartan/hydrochlorothiazide).

  Journal of clinical hypertension (Greenwich, Conn.) 20010101

• Telmisartan: a review of its use in hypertension.

  Drugs 20010101

• Use of ambulatory blood pressure monitoring to evaluate the selective angiotensin II receptor antagonist, telmisartan, and other antihypertensive drugs.

  Blood pressure monitoring 20000101

• Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension.

  American journal of therapeutics 19990501

• Telmisartan.

  Drugs 19981201

• Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 19980201

• Differential regulation of mesenteric and femoral blood flow in the rat as revealed by computerized data acquisition and evaluation.

  Journal of autonomic pharmacology 19980201

• Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.

  British journal of pharmacology 19930901